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Abstract 
 
BACKGROUND:  Colorectal cancer is the second most common cancer in Norway, with the 
incidence rate increasing for both men and women. Patients with colorectal cancer commonly 
experience metastases in the liver. In Norway, about 30% of patients will have liver 
metastases at the time of diagnosis, and another 20% will develop metastases during the 
course of their treatment. Because interventions aimed at curing or managing this disease may 
have a negative impact on patient health, measuring patient outcomes in the form of health-
related quality-of-life is important to assess the relative benefits of these interventions to 
patients. Disease specific health-related quality-of-life measures have been found to be more 
sensitive to the health states of patients, however the disease specific measure used for 
assessing health-related quality-of-life in colorectal cancer patients with liver metastases has 
previously not been available in the Norwegian language. 
 
OBJECTIVE:  This cross-sectional study seeks to explore the methods used in the translation 
and psychometric assessment of health-related quality-of-life instruments and preliminarily 
assess the quality of the Norwegian EORTC-QLQ-LMC21 in terms of validity, reliability, 
responsiveness and equivalence with the English version. 
 
METHOD: This study is divided into two parts: (1) the qualitative translation process; and (2) 
the qualitative psychometric assessment of the resulting translated instrument. The EORTC-
QLQ-LMC21 was first translated from English into Norwegian according to the 
recommendations of the instrument's governing body. The process was documented and the 
quality of the translation qualitatively assessed through translator feedback, content validity 
exploration, and patient feedback and acceptance. The validity, reliability, responsiveness, 
and equivalence of the translated questionnaire were then quantitatively assessed using 
Pearson's Product Movement of Correlation, Cronbach's alpha, and floor and ceiling effects.  
 
RESULTS:  The EORTC-QLQ-LMC21 had good patient acceptance and performed fair to 
good on tests of validity, reliability, responsiveness and equivalence. The psychometric 
performance of the abdominal pain scale was poor due to one particular item, but there is 
nonetheless preliminary evidence for an acceptable level of quality and ability to 
meaningfully measure the health-related quality-of-life of this patient group.   
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1 Introduction 
Measurement is the assigning of numbers to observations in order to quantify phenomena 
(Kimberlin & Winterstein, 2008). In health care, this may mean measuring biological 
indicators for the presence of disease, or measuring a more abstract concept such as health-
related quality-of-life (HRQoL). The goal of HRQoL measurement is to assess patient health 
as it is affected by intervention or disease, but in a way that ensures that data is free from 
measurement error and can be meaningfully interpreted. To accomplish this, reliable, valid, 
and responsive measurement instruments are needed.  
HRQoL has gained increasing importance as a health outcome measure in economic 
evaluations performed alongside randomized clinical trials (RCTs). Economic evaluations 
seek to systematically measure and value the costs and benefits of two alternative 
interventions so they may be meaningfully compared and the best course of action identified 
(Drummond, 2005). Before the introduction of the patient perspective in the form of HRQoL, 
RCT investigators relied only on the measurement of biological indicators, such as survival 
time. While survival time has continued to be a very important end point measured in RCTs, 
the introduction of the patient perspective in health outcome measurement has provided a way 
for doctors and researchers to more accurately assess the actual relative benefit of treatment to 
the patient. 
This has become especially important in the evaluation of interventions for patients with 
chronic and severe conditions, such as cancer. Cancer patients are some of the most severely 
affected by interventions that aim to either lengthen survival time or offer a cure for the 
disease. Because patients with cancer have many symptoms and losses of function that cannot 
be measured with laboratory tests, multi-dimensional health outcome measurement in the 
form of HRQoL is increasingly used to evaluate the effect of cancer interventions.  
This study will focus on the measurement of HRQoL for colorectal cancer (CRC) patients 
with liver metastases, as the instrument that is the focus of this study, the EORTC-QLQ-
LMC21 (QLQ-LMC21), is an HRQoL instrument designed specifically for this patient group. 
Using a cross-sectional study design, this analysis ultimately seeks to explore the methods 
used in the translation and psychometric assessment of HRQoL instruments and preliminarily 
assess the quality of the Norwegian QLQ-LMC21 in terms of equivalence, validity, reliability 
and responsiveness. The analysis focuses on the QLQ-LMC21 questionnaire and its validity, 
reliability, and responsiveness by exploring: 
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A. Content validity, patient acceptance, and equivalence achieved through the translation 
process 
B. Psychometric validity at item-level by evaluating internal consistency, convergent 
validity and discriminant validity 
C. Reliability, validity and responsiveness at scale-level by comparing the QLQ-LMC21 
to the SF-36 and QLQ-C30 
a. The hypothesis/assumption that the QLQ-LMC21 is more sensitive 
(responsive) to small, yet clinically important changes in the health of patients 
with CRC liver metastases 
This introduction included a brief introduction of HRQoL measurement in economic 
evaluations alongside RCTs that seek to evaluate interventions for cancer patients. In chapter 
two I will place this study in the context of the Norwegian setting by discussing CRC in 
Norway and the RCT being conducted in Oslo that seeks to evaluate the effectiveness of a 
new treatment method for patients with CRC liver metastasis, the CoMet study. In chapter 
three I will define and discuss the concepts of health, HRQoL, and health measurement. I will 
also discuss the development of HRQoL instruments, including the three instruments used in 
this study. In chapter four, I will discuss the concepts that underlie the methods for instrument 
translation and the development and assessment of valid, reliable and responsive HRQoL 
instruments that are capable of yielding meaningful data. Chapter five contains patient, data 
and study methods used in the analysis, followed by results in chapter six. Chapter seven will 
contain a study discussion, followed by a conclusion in chapter eight. 
Because this study explores two processes (translation and psychometric assessment) that are 
approached using different methods (qualitative and quantitative, respectively), chapters four, 
five, and six have been divided accordingly:  (1) the translation process and (2) the 
psychometric assessment. 
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2 Background 
Cancer is currently the second leading cause of death in the world, including Norway. In 
2012, 10,800 of the 41,900 deaths (25.8%) in Norway were attributed to cancer (Borgan, 
2013). The incidence of CRC is increasing and is now the third most prevalent form of cancer 
and the fourth leading cause of cancer deaths worldwide, with an estimated 1.2 million cases 
and .6 million deaths annually (von Karsa et al., 2013). Estimates by the International Agency 
for Research on Cancer place CRC as the most common cancer in Europe, with 432,000 new 
reported cases for men and women in 2008 (Ferlay, 2010). CRC is the second most 
commonly diagnosed cancer in Norway, and the incidence is rising for both men and women 
(Hviding, Juvet, Vines, & Fretheim, 2008).  Patients with CRC may experience metastasis, or 
spreading, of the cancer to other organs.  Commonly with CRC, the metastasis may occur in 
the liver. In Norway, about 30% of patients present with metastases at the time of diagnosis, 
while another 20% develop metastases during the course of the disease (Hviding et al., 2008).  
Though chemotherapy may be used to manage advanced disease, hepatic (liver) resection is 
the only potentially curable treatment and is now offered to 20-25% of patients with liver 
metastases. Five-year survival rates for this surgery are currently between 30% and 58% 
(Abdalla et al., 2004).	   
The HRQoL instrument that is the focus of this analysis, the QLQ-LMC21, was translated 
into Norwegian during this study for eventual use in the Oslo CoMet study. The QLQ-
LMC21 is specifically designed to measure the HRQoL in patients whose CRC has 
metastasized to the liver, and the CoMet study is a currently operating RCT that is designed to 
determine whether laparoscopic liver resection of colorectal liver metastases leads to less 
postoperative morbidity and mortality than open liver resection. Secondary end points of the 
RCT include 5-year survival, disease-free and recurrence-free survival, recurrence pattern, 
and management of recurrence (Fretland et al., 2015). 
An economic evaluation is also being conducted alongside the RCT to ascertain the hospital 
and societal costs and the benefits to patients as a result of treatment. Cost data will be 
assessed using registry data and patient questionnaires. HRQoL is currently assessed using the 
Short-Form-36 (SF-36). The SF-36 is given to patients before surgery (baseline), and at 1-
month and 4-months post-surgery. The SF-36 is a generic HRQoL measure that is designed to 
measure the HRQoL in a broad range of patients regardless of the type of disease. 
Additionally, a subset of patients will receive the disease specific HRQoL instrument, the 
	  	  
	  
4	  
QLQ-LMC21. As this measure is newly translated into Norwegian as a result of this study, it 
has never before been used in a RCT in Norway. Additionally, it has never before been used 
to evaluate the HRQoL of patients undergoing liver resection (Fretland et al., 2015). 
During the last two decades, economic evaluations have been used in response to the dramatic 
increase in health care expenditure caused by rapidly expanding medical technology and an 
increase in patients living longer with more chronic diseases, such as cancer. Since 1997 in 
Norway, for example, total health care expenditure has increased 67.6%, from NOK 
88,369,000,000 in 1997 to NOK 272,911,000,000 in 2013. Current preliminary estimates 
show 2014 expenditures at NOK 290,000,000,000 (Øynes, 2015).  Figure 1 shows the steady 
increase in health expenditure in Norway since 1997. 
Economic evaluations are used in clinical trials to collect data on the costs and effects of 
interventions (Glick, 2015). The cost of the intervention is compared to the effect data, often 
measured in HRQoL, to assess the relative benefit of the intervention to the patient. This 
assessment is important because many costly new interventions may either yield very little 
actual benefit to patients in HRQoL or survival time, or they may in fact detrimentally affect 
patient health. Economic evaluations seek to assess the relative benefit of the intervention to 
the patient so that policy makers can make informed decisions regarding the allocation of 
increasingly constrained resources in the health sector. 
 
Source: Statistics Norway 
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3 Measuring health 
The WHO defines health as "a state of complete physical, mental and social well-being and 
not merely the absence of disease or infirmity" (WHO, 1948). While this definition is thought 
by some to be idealistic and lacking an operational definition, it nonetheless recognizes the 
multi-dimensionality of health and has allowed for a paradigm in modern medicine that 
incorporates both tangible biological indicators and intangible quality-of-life perceptions.  
Like the concept of health, HRQoL is multi-dimensional and can be defined in many ways, 
but at a minimum it involves an assessment of the physical, mental, and social effects of 
disease or treatment on the patient (Ferrans, Zerwic, Wilbur, & Larson, 2005). In other words, 
it is the way in which health is affected by disease and treatment. HRQoL is differentiated 
from general quality-of-life (QoL) in that it is only concerned with the ways in which disease 
and interventions affect health. Originally, work in this area was termed "health status" or 
"outcomes assessment" and could be performed in either patients or the general public. 
Eventually, the outcomes of these assessments being performed on patients were termed 
HRQoL assessment to distinguish it from general QoL, because QoL can be influenced by 
factors that lie outside of the health domain, such as income or environmental factors (Osoba, 
2011).  
The purpose of measuring health is to quantify the degree to which disease or treatment 
impacts the patient (ISOQOL, 2015). This purpose has gained even more importance since the 
1990’s with the development and expansion of the evidence-based decision-making paradigm 
(Bensing, 2000). The goal of evidence-based decision-making is to systematically review, 
appraise, and use clinical research findings to aid in the delivery of optimum clinical care to 
patients (Rosenberg, 1995). Increasingly, these methods are being employed to aid in 
decisions regarding resource allocation, namely in the form of economic evaluations 
alongside clinical trials. 
In this chapter I will start by generally discussing HRQoL instruments and their general 
purpose. I will then discuss generic, utility-based, and disease-specific instruments by 
exploring their construction and purpose. I will also introduce and discuss in detail the 
measures that are the subjects of this study, the SF-36, QLQ-C30, and QLQ-LMC21.    
3.1 Health-related quality-of-life instruments 
Multi-dimensional definitions of health recognize that health is a product of the tangible and 
intangible, the objective and the subjective. This has led to two broad categories of health 
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measurement: objective health measurement and perceived health measurement. Objective 
health lies outside of the perceptions, feelings, and thoughts of the patient and can be 
measured with clinical indicators, such as by tumor size, weight loss, or survival time. 
Though objective health measurement continues to be an important component of health 
outcomes research, this study will focus on perceived health and its measurement. Perceived 
health is the aggregate subjective experience of biological function, symptoms, and functional 
status and can be measured using patient-reported-outcome (PROs) assessments. PROs give a 
subjective view of the health of patients as they experience it, without being interpreted by a 
clinician and recognize that patient perceptions are influenced by individual and 
environmental factors that vary from patient to patient (Wilson, 1995). For example, though 
two patients may be afflicted with the same type of cancer with identical tumors in identical 
locations in the body, due to biological, psychological or socio-economic qualities, and traits 
unique to those patients, they may experience the effects of their disease and treatments 
differently. PRO assessments can assess a wide variety of patient experiences, from 
satisfaction with treatment to the burdens of disease symptoms on day-to-day life.  
HRQoL instruments are a specialized type of PRO assessment used by clinicians, researchers, 
and policy makers that seek to measure QoL as it is affected by disease and treatment 
(Blazeby et al., 2006). The development of valid, reliable, and responsive instruments since 
the 1970's has resulted in the assessment of HRQoL in tens of thousands of cancer patients in 
thousands of clinical trials. These measures have become especially useful in the assessment 
of the impacts of toxic and invasive treatments, such as chemotherapy and surgery, by 
assessing the subjective relative benefit of these treatments on patient QoL.  
There are three broad types of HRQoL measures: generic, utility-based, and disease-specific. 
The choice of instrument largely depends on two factors: the extent to which the investigator 
wishes to capture health status change over time, and the desire to measure within-subject 
change versus between-subject change (Patrick, 1989).  Though the focus of this paper is a 
disease-specific instrument, the QLQ-LMC21, I will begin my discussion of HRQoL 
instruments with generic instruments, as they are the broadest type of HRQoL instrument. 
Discussing them first will lay the groundwork for the increasingly narrow scope of the other 
two instrument types, utility-based and disease-specific, respectively.  
3.1.1 Generic HRQoL instruments 
Generic instruments aim for a broad assessment of HRQoL and can be administered to 
patients regardless of impairment, illness, or disease because the outcome is expressed in a 
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standard unit of measure. They are used for their ability to capture a comprehensive picture of 
HRQoL across all patient populations that can then be used to evaluate treatments, allocate 
resources, or compare disease burden between patient groups. The same generic measure can, 
for example, be administered to a patient diagnosed with arthritis or a patient diagnosed with 
CRC, and their scores can be meaningfully compared because of the standard unit of measure.  
Due to their robustness and wide breadth of health states they are able to capture, generic 
instruments have a good capacity to measure HRQoL in a diverse set of patients. They are 
attractive to researchers and policy makers because they make comparisons between patient 
populations possible (G. Guyatt, Feeny, D., Patrick, D., 1993). When assessing the benefits of 
an intervention, the policy maker may be more interested in between-subject change 
(examining differences between individuals) at one particular time point. They may also wish 
to compare health outcomes across patient groups and interventions, which is not possible 
with disease-specific measures. They, therefore, may be more inclined to choose a generic 
HRQoL instrument. Examples of generic HRQoL instruments are the SF-36, the Sickness 
Impact Profile, and the Nottingham Health Profile. 
Paradoxically, the disadvantages of generic measures are a direct consequence of their 
robustness. Because generic measures tend to be necessarily long in order to measure HRQoL 
in such a large range of patients, patients may be less likely to complete these longer measures 
or more likely to fill them out incompletely, leading to a lower response rate or gaps in 
individual data. While some measures, like the SF-36, have algorithms that try to estimate 
missing values based on other completed answers, some investigators may not find this an 
ideal solution. 
Generic measures have also been found to be less sensitive, or responsive, to small yet 
clinically significant changes in health (G. Guyatt, Feeny, D., Patrick, D., 1993). Their ability 
to measure the health states of so many types of patients causes them to be less able to focus 
on the problems of any one particular patient group. These measures are also less able to 
measure small but meaningful changes in patient health over time, making them less attractive 
to researchers who are interested in evaluating the effects of a specific intervention on patient 
outcomes. 
3.1.1.1 SF-36 
The SF-36 was constructed in order to make comparisons of HRQoL, relative disease burden, 
and relative benefits of treatment between groups possible for the researchers and policy 
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makers involved in the Medical Outcome Survey (MOS), which was a 2-year observational 
study designed to help understand how specific components of the public health care system 
in the U.S. affect health outcomes (Stewart, 1989).  
Prior to its development in 1988, there was a lack of measurement tools suitable for large-
scale use across diverse patient populations. Standardized general health measures had been 
found useful for smaller scale research because they assessed basic human values such as 
functioning and emotional well-being. But due to their length, they were found to be 
impractical for large-scale use, such as in the MOS (J. E. Ware, Sherbourne, C., 1992). 
Brevity, reliability, and validity were the goals of the SF-36 developers. Its 8 dimensions and 
36 items represent the most frequently measured HRQoL concepts found in widely used 
health surveys used since the 1970's and 1980's (J. E. Ware, Gandek, B., 1998). Today, the 
SF-36 is one of the most used HRQoL instruments worldwide; a literature search found over 
3,000 studies that have been undertaken using the instrument.  
The SF-36 currently in use is the second version of the instrument. It consists entirely of 
functional scales (scales intended to measure the extent to which the patient experiences 
various functional limitations as a result of treatment or disease) and one single item question 
regarding health transition. Because it is not designed to assess the symptoms associated with 
any one disease, it does not contain either symptom scales or symptom single-items as many 
disease-specific measures do.  
Its 36 questions are spread over eight dimensions: physical functioning, physical role 
functioning, emotional role functioning, bodily pain, vitality, social functioning, mental health 
and general health, plus one single item for health transition status. (Kuenstner, 2002) These 
eight domains aggregate to form physical and mental health summary scores. The single item 
on health transition status is not used to calculate the scale scores, but has been found to be 
useful in estimating average change in health in the year previous to instrument administration 
(J. E. Ware, Gandek, B., 1998). In addition, the SF-36 has a utility index that uses an 
algorithm to derive utility scores that can be used to calculate quality-adjusted-life-years 
(QALYs) for use in economic evaluations. 
The SF-36 is designed to be self-administered. Items are answered in a Likert scale continuum 
format. However, both the range of responses and the severity continuum order (not affected 
to very affected vs. very affected vs. not affected) for the responses are different for each 
question. For example, question 7 and 8 are both items in the bodily pain scale, however 
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question 7 has a scale with six possible answers, while question 8 only has five possible 
answers. Their severity continuum is, however, the same; an answer of 1 indicates no problem 
with pain, while the opposite end of the scale indicates a great deal of pain. SF-36 items and 
scales can be found in Table 1. 
3.1.2 Utility-based instruments 
Utility-based instruments, such as the SF-6D and EQ-5D, are a specialized type of generic 
instrument that measure the utility, or preference, that a patient has for a particular health 
state. Like generic measures, they can be given to patients regardless of diagnosis and can be 
used to compare outcomes across patient groups.  
They often measure similar dimensions of health as generic measures, but they incorporate 
preference weights to calculate a single preference-based index score of health (Patrick, 
1989). Preference weights are created using econometrically derived (using an estimator to 
represent and predict a statistical relationship) valuation methods using general population 
values. Subjects, usually members of the general public, are asked to imagine being in 
particular health states and then must score their preference for being in that health state. 
Valuation methods include the visual analog scale (VAS), standard gamble (SG), and time-
trade-off (TTO). In the VAS method, subjects simply rate the health state on a scale from 
most to least preferable. The SG and TTO methods involve the subject having to value an 
imaginary health state by either trading life-years or risking immediate death in order to avoid 
the health state in question. The preference weights, also called tariffs, derived from these 
methods are then applied to the scores of the utility-based instruments in the calculation of the 
index score for a patient.  
The index score derived from these instruments is scaled in reference to the absolute reference 
points 0, indicating death, and 1, indicating best health possible. Negative values are also 
possible with some utility-based instruments, and indicate a state that is experienced as 
“worse than death”. For example, a patient with an index score of 1 is regarded as being in 
perfect health, while a patient who has an index score of -0.2 is considered to be in a very 
poor health state that is perceived to be worse than death. The index score can either stand as 
an overall measure of preference-based HRQoL or can be combined with life years to 
calculate QALYs. These single index instruments can have a considerable advantage over 
profile-based instruments, such as the SF-36, because of the high degree of interpretability 
that the index score offers. 
	  	  
	  
10	  
Utility-based instruments are used in the economic evaluations of health interventions because 
they offer a way for decision makers to systematically compare relative disease burden and 
intervention effectiveness between different patient groups, as well as their ability to help 
generate QALYs. QALYs are used in economic evaluation to compare the cost per quality-
adjusted-life-year gained from different health interventions across patient groups (Patrick, 
1989).  
Though desirable for their ability to standardize and compare the health benefits of 
interventions across patient populations and programs, these measures and their results are not 
without controversy. The valuation methods used to create preference weights have been 
criticized for being biased and not representative of the true patient experience because of the 
very cognitively difficult task of imagining health states that one has never experienced. 
Problems with the full health and death anchors have also been documented due to varying 
attitudes and perceptions around health and death, leading to potentially biased tariffs that 
may distort the index score (Augestad, Rand-Hendriksen, Stavem, & Kristiansen, 2013).  
3.1.2.1 SF-6D 
The SF-6D is a utility-based instrument that estimates preference-based index scores derived 
from a selection of SF-36 scores. The SF-6D is not a self-standing HRQoL instrument that is 
completed by respondents, but rather its score is derived from eleven items from the SF-36. 
To obtain a SF-6D score, an algorithm is applied to a completed SF-36 questionnaire that then 
yields a single preference weighted index score that ranges from .29 (worst health) to 1 (best 
health).  
The SF-6D consists of six domains from the SF-36: physical functioning, role limitations, 
social functioning, pain, mental health, and vitality, with four to five levels of severity for 
each, giving a total of 18,000 possible health states. From these possible health states, 249 
were selected and valued using the standard gamble technique from a UK population sample. 
An algorithm for transforming SF-36 data into a single index score was constructed using 
regression models to predict the single-index score of the SF-6D index items. (Mutebi, 2011). 
3.1.3 Disease-specific HRQoL measures  
Disease-specific instruments are narrower in their design than their generic and utility-based 
counterparts and are meant to measure the HRQoL related to a particular condition. They are 
designed to assess specific diagnostic groups or patient populations, often with the goal of 
measuring clinically significant changes in health that clinicians think are important. 
Examples of disease-specific measures are the Beck Depression Inventory, Arthritis Impact 
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Measurement Scale, and the QLQ-C30 with the QLQ-LMC21 subscale. Though they may 
share dimensions in common with generic measures, such as pain or mobility, disease-
specific measures tend to have items, wording, and instructions that are tailored to the target 
patient population. They are written by consulting with doctors and patients to find the 
problems most associated with the specific diagnosis or symptom (Patrick, 1989).  
Because disease-specific measures are designed to capture the problems experienced by a 
particular patient group, they are purported to be more sensitive to the health states that these 
patients experience and are able to detect small movements in health status, also known as the 
responsiveness of an instrument (Patrick, 1989). The responsiveness of disease-specific 
instruments is a main benefit of their use; though a generic and specific measure may both 
have a pain domain, the generic measure will not have questions that are designed to 
specifically capture a symptom associated with that particular disease or disease intervention, 
for example, abdominal pain for a patient diagnosed with CRC liver metastasis. In an RCT 
evaluating the effect of an intervention for this patient population, this facet of the health state 
would be lost with a generic measure and that facet of patient health would appear to be 
unaffected by the intervention. 
It is common for disease-specific measures to be used by clinicians in their clinical work with 
patients or by investigators administering RCTs. Disease-specific measures are useful in 
achieving the goals intrinsic to both daily clinical work with patients and RCTs, namely the 
within-subject change (how much a patient changes over time) in health outcomes over a 
period of time in order to evaluate the effectiveness of a treatment. They help clinicians and 
researchers to distinguish between improved and unimproved patients, and accurately 
measure clinically significant changes in the health states of patients (Patrick, 1989). 
Due to a lack of a standard unit of measure between disease-specific measures, they may be of 
less use when researchers wish to compare health outcomes across different diseases and 
programs, and can also not be used to calculate QALYs. Using only a disease-specific 
measure in an RCT may be limiting to researchers who wish to perform an economic 
evaluation alongside a clinical trial. 
3.1.3.1 QLQ-C30 
The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life 
(QoL) Group was formed in 1980 in response to the need to advise EORTC on the design, 
implementation, and analysis of QoL studies in cancer clinical trials, and in 1986 they began 
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to develop an integrated measurement system for evaluating the QoL of patients participating 
in international cancer clinical trials (N. Aaronson, Ahmedzai, S., Bergman, B., Bullinger, M., 
Cull, A., Duez., N., Filiberti, A., Osoba, D., Sullivan, M., , 1993). Because of practical 
constraints within clinical trials, the EORTC QoL Group sought to have a brief instrument 
that was still capable of capturing small yet clinically significant changes in health status. To 
achieve this, they adopted a modular approach to HRQoL instruments, with a core cancer 
measure, the QLQ-C30, which could be supplemented by diagnosis-specific modules, such as 
for CRC liver metastases or breast cancer (N. Aaronson, Cull, A., Kaasa, S., Sprangers, M., 
1994). The EORTC Quality of Life Questionnaire (QLQ)-C30 is the most commonly used 
HRQoL instrument used in European cancer RCTs, and has been used in over 3,000 studies 
worldwide (EORTC, 2015).   
In designing the QLQ-C30, the EORTC research group wished to build upon the conceptual 
and methodological framework for health status assessment that Ware et al. developed in their 
work with the SF-36 in the US (J. J. Ware, 1984) (J. J. Ware, Brook, R.H., Davies-Avery, A., 
1980). They found this framework valuable, but tailored their work to cancer patients and 
placed signs and symptoms of cancer at the core of HRQoL measurement, followed by 
personal functioning, mental/emotional distress, general health perceptions, and social role 
functioning.  
There were several cancer specific questionnaires in use in the 1980's, however none had been 
sufficiently validated. Before beginning the development of the QLQ-C30, the group defined 
several criteria for its construction: (1) the measure should be specific to cancer; (2) be 
designed primarily for patient self-administration; (3) be multi-dimensional and cover at least 
four basic QoL domains -- physical symptoms, physical and role functioning, psychological 
functioning, and social functioning; (4) be comprised primarily of multi-item scales; (5) be 
relatively brief. Additionally, the measure had to meet standards set for reliability, validity, 
and responsiveness, as well as be suitable for use cross-culturally while maintaining statistical 
validity (N. Aaronson, Cull, A., Kaasa, S., Sprangers, M., 1994). 
The current QLQ-C30 is the third version of the questionnaire. It has 30-items and is 
composed of both multi-item scales and single items that reflect the multi-dimensionality of 
the HRQoL construct as it relates to the broad spectrum of cancer patients irrespective of 
body-site-specific diagnoses (N. Aaronson, Ahmedzai, S., Bergman, B., Bullinger, M., Cull, 
A., Duez., N., Filiberti, A., Osoba, D., Sullivan, M., , 1993). The QLQ-C30 contains five 
functional scales that assess physical, role, cognitive, emotional and social functioning, three 
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symptom scales that assess fatigue, pain and nausea/vomiting, and a global HRQoL scale. It 
also contains several single-item symptom items for dyspnoea, insomnia, appetite loss, 
constipation, diarrhea, and financial difficulties which are meant to assess symptoms common 
to cancer patients (Kuenstner, 2002). 
The QLQ-C30 is designed to be self-administered. Respondents are asked to consider their 
health during the last one week for 25 of the 30 questions. There is no time period specified 
for the remaining 7 questions, as it is implied that respondents generally consider their health. 
All questions, with the exception of the two global HRQoL questions, are answered in a 
Likert scale continuum format on a scale ranging from 1-4. An answer of 1 indicates "Ikke i 
det hele tatt", or they have not at all been affected by the health concern in question, an 
answer of 2 indicates "Litt", or they have been a little affected by the health concern in 
question, an answer of 3 indicates "En del", or that they have been partly affected by the 
health concern in question, and an answer of 4 indicates "Svært mye", or they have very much 
been affected by the health concern in question. The two questions in the global HRQoL scale 
are also answered in a Likert scale continuum format, however, the range of answers is 
expanded and ranges from 1-7. A patient who answers 1 on the scale indicates that their 
health as "Svært dårlig", or very bad, whereas an answer of 7 indicates they are "helt 
utmerket", or in excellent health. All domains and item numbers for the QLQ-C30 can be 
found in Table 2. 
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3.1.3.2 QLQ-LMC21 
The QLQ-LMC21 is one of among 19 body-site specific modules developed by EORTC. It 
was designed specifically to measure the HRQoL of patients with CRC who have developed 
liver metastases. It was developed per EORTC guidelines through semi-structured interviews 
with patients and health care professionals at six cancer hospitals in the UK, France, and 
Germany in 2002 (Kavadas et al., 2003). The QLQ-LMC21 is the only instrument designed to 
measure HRQoL in patients with CRC liver metastases. Prior to its development, there were 
only instruments that were designed to assess the HRQoL of patients with CRC with no liver 
metastases, which concentrated on the gastrointestinal side effects of treatment and symptoms 
for this type of cancer, such as stomas and bowel and sexual function.  Because the symptoms 
and side effects of the disease and treatment for CRC patients with liver metastases are 
different from CRC patients with no liver metastases, it was hypothesized that these 
instruments designed for CRC patients may be insensitive and irrelevant to patients 
undergoing treatment for CRC with liver metastases (Kavadas et al., 2003). 
Blazeby et al. tested the reliability and validity of the English language version of the 
instrument in 2009 and found it to be a reliable and valid measure (Blazeby et al., 2009). The 
availability of studies on the QLQ-LMC21 is currently limited, especially in languages other 
than English. This study is the first to undertake the translation process in Norwegian, and 
Magaji et al. have recently translated the measure into the Maylasian Chinese and Tamil 
languages and are currently testing the measure for validity and reliability (Magaji et al., 
2012). 
The QLQ-LMC21 contains 21 items that are split into four scales assessing abdominal pain, 
activity/vigor, eating problems, and anxiety, and nine single-item symptom items that assess 
taste problems, dry mouth, sore mouth/tongue, peripheral neuropathy, jaundice, sexual 
function, nutritional issues, contact with friends, and talking about feelings (Rees et al., 2012). 
All domains and item numbers for the QLQ-LMC21 can be found in Table 3. 
The QLQ-LMC21 is designed to be self-administered and given to patients as a seamless 
supplement to the QLQ-C30, meaning that the QLQ-C30 and QLQ-LMC21 are intended to be 
presented to the patient as one unit. The QLQ-LMC21 continues the item-numbering scheme 
of the QLQ-C30 and begins its numbering with question 31 (the final question of the QLQ-
C30 is 30), giving the patient a total of 51 items. Also like the QLQ-C30, the items are 
answered in a Likert scale continuum format. All items range on a scale from 1-4, with 1 
indicating not affected at all by symptoms and 4 indicating being effected a great deal. 
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Respondents are asked to consider their health during the last one week for 20 of the 21 
questions. The remaining one question asks respondents to consider their health during the 
past four weeks.  
 
 
	  	    
	  	  
	  
16	  
4 Concepts in HRQoL measurement 
The measurement of HRQoL combines the desire for high quality instruments with the 
empirical rigor increasingly found in modern health cares systems. In this chapter, I will 
discuss the concepts that have been developed to aid in the creation of HRQoL instruments 
that are able to meaningfully measure HRQoL.  Because the translation of the QLQ-LMC21 
forms the basis of this study, I will begin by discussing concepts behind the translation of 
instruments and how researchers assess the quality of translations in terms of content validity 
and equivalence with the original questionnaire, and recommended translation methods for 
achieving content validity and equivalence. I will then continue by discussing the concepts 
that underpin the construction and psychometric assessment of HRQoL measures in terms of 
validity, reliability, and responsiveness. 
4.1 Translation of HRQoL instruments 
With few exceptions, most HRQoL measures are developed in the English language and are 
intended for use in English speaking countries (Guillemin, 1993). The increasing interest in 
measuring HRQoL world-wide, and increasing numbers of multi-national RCTs with a need 
to compare results across different countries, cultures, and language groups has led to the 
need for HRQoL measures to be translated and cross-culturally adapted. Because of language 
and cultural differences, simply transposing the measure from English into the target language 
will not necessarily yield a valid instrument that maintains equivalence with the original. For 
an instrument to yield meaningful results that can be compared across cultures, it must not 
only be translated linguistically well, it must also be culturally adapted to maintain the content 
validity and equivalence at a conceptual level. These considerations in the translation and 
adaptation process lead to confidence that the disease burden and health outcomes of 
interventions are being accurately measured (Beaton, 2000).  
4.1.1 Content validity 
Validity is the extent to which the instrument measures its intended constructs, for example 
anxiety or fatigue. Content validity is a type of validity that addresses how well the items in 
the instrument provide an adequate sample of all items that might measure the construct of 
interest. Because there is no statistical measure that can be applied to this assessment, it is a 
more subjective form of validity and is often left to the judgment of experts in the field and is 
often called face validity. 
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4.1.2 Equivalence 
Equivalence is an important concept and consideration in the translation of HRQoL 
questionnaires. Equivalence is defined as the extent to which an instrument does what it is 
designed to do equally well in both the original and translated version. Though there is little 
consensus in the literature regarding its definition, equivalence essentially means that the 
scores from the groups taking the original questionnaire and translated questionnaire can be 
meaningfully compared (Herdman, 1998). A layered and systematic translation method is 
needed to achieve a translated measure that maintains cross-cultural equivalence. The 
translation procedure guidelines put forth by EORTC to guide the translations of their 
measures, such as the QLQ-C30 or QLQ-LMC21, are based on research by Brislin (Brislin, 
1970) and Hambleton (Hambleton, 1993) and further developed by Beaton et al. in 2000 
(Beaton, 2000). The back-translation framework of these theories aims to help maintain the 
conceptual, linguistic, cultural, and functional equivalence between the translated and original 
questionnaire (Dewolf, 2009).  
Conceptual, linguistic, and cultural equivalence are each important components that support 
the overall equivalence of a translated questionnaire. Conceptual equivalence is achieved 
when the relationship to the underlying HRQoL concepts are the same in both the original and 
translated questionnaires. Linguistic equivalence is concerned with the transfer of meaning 
across languages, and similar effect on respondents in different languages. Cultural 
equivalence is concerned with assuring that takers of the measure in both languages are 
working under the same set of assumptions and expectations about the assessment. Some 
problems that may arise with cultural equivalence are differing levels of test motivation, 
unfamiliar test formats, and variable experiences and values (Hambleton, 1993).  
4.1.3 Translation methods to achieve content validity and equivalence 
Brislin, Hambleton, and Beaton recommend the following rigorous, iterative, and multi-
layered back-translation process that supports the creation of an equivalent instrument. This 
process begins with the selection of two translators who should independently complete the 
forward translation from the original (source) language to the target language, and two 
translators who should independently complete the backwards translation from the target 
language back to the source language. The translators should have expertise in both the target 
and source languages and familiarity with both cultures, otherwise they may not be as 
sensitive to the unique patterns of the target and source language and culture that will allow 
for both a natural sounding and equivalent instrument (Hambleton, 1993). After the forward 
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translations are independently completed, the translators should meet to discuss their 
translations and come to a consensus on a synthesized translation that will be used in the 
backward translation process.  
During the backward translation process, two translators independently translate the 
instrument back to the source language. This is done as a general check of the quality and 
content validity of the forward translation. It helps to highlight gross inconsistencies or 
conceptual errors, and helps to ensure that the questions have been translated in such a way 
that the instrument retains equivalent meaning to the source questionnaire. Backward 
translators can also help to fix grammatical or spelling errors in the forward translation. 
Expert panels should review all translations after they are completed to further ensure the 
content validity and quality of the translated instrument. The role of the expert committee is to 
review and consolidate all versions of the questionnaire into what is considered a first 
intermediary version (FIV) for use in pilot testing. During the review and consolidation phase, 
the committee should critically evaluate the conceptual, linguistic, and cultural equivalence 
between the original and translated instrument to reach a consensus about any discrepancies 
and recommend alterations before pilot testing begins (Beaton, 2000).  
The pilot test should be conducted on members of the target population to provide insight into 
the content validity of the instrument, as well as to identify difficult items or wording. Both 
the meaning of items and responses are explored to ensure that the equivalence of the measure 
is retained not only in theory, but also in an applied setting (Beaton, 2000). 
The final stage in the translation and adaptation process should be a written technical report 
submitted to the instrument’s developers. It is used to document the integrity of the process, 
the evolution of the translated instrument, and to maintain transparency of methods and 
quality. Developers use this report to ensure that all stages of the translation were well 
executed to produce a reasonable and quality translation. 
Though the concepts of equivalence are evaluated by mostly qualitative methods through the 
iterative backward-translation process and exploration of content validity, equivalence can 
and should also be assessed quantitatively, and can be done by testing the retention of the 
psychometric properties of the questionnaire (Beaton, 2000).   
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4.2 Construction and psychometric assessment of HRQoL instruments 
Measurement of HRQoL involves the operationalization of theoretical constructs, such as 
emotional role functioning or pain, and the development of instruments that are able to 
quantify them (Kimberlin & Winterstein, 2008). All measures are constructed by first 
defining several domains to measure the desired HRQoL concepts relevant to the intended 
patient group1. The range of domains that may be present in HRQoL measures is quite 
diverse, but instruments usually include physical, emotional (or psychological), and social 
domains. They may additionally include other domains such as cognitive functioning, 
sexuality, and spirituality (Osoba, 2011). 
Domains are uni-dimensional, meaning they are intended to measure only a single concept, 
and can be defined as either a symptom scale or a functional scale, such as pain or cognitive 
function, respectively. A symptom scale is intended to measure the extent to which the patient 
experiences various symptoms as a result of treatment or disease, such as pain, while a 
functional scale is intended to measure the extent to which the patient experiences various 
functional limitations as a result of treatment or disease. Often times, the scoring for symptom 
scales and functional scales is reversed in order for the scores to be intuitively interpreted. For 
example, a low score on a symptomatic pain scale would indicate low symptoms of pain, 
while a high score on a cognitive functioning scale would indicate high cognitive functioning.  
After the desired domains are defined depending on what has been deemed relevant to the 
patient group in question, items (questions) are written within each domain with the 
assumption that they will measure the underlying HRQoL domain concepts. Some measures 
may consist of a single global domain of general QoL, and may only ask a single question, 
such as "How is the quality of your life?" But because the information gathered from such a 
measure fails to address the multiplicity of factors that coalesce to determine HRQoL, it may 
not be very clinically useful. Most HRQoL measures are designed to include several different 
domains that consist of several items in an attempt to capture a robust picture of patient health 
(G. Guyatt, Feeny, D., Patrick, D., 1993).  
Because HRQoL is a theoretical construct, it is more difficult to quantify and measure than 
traditional objective medical markers. Consequently, HRQoL researchers have borrowed 
strategies from the field of psychometrics, which is the study of the theory and technique of 
psychological measurement. The fields of psychometrics developed in response to the need of 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  The terms domain, dimension, and scale are often used interchangeably and refer to a component of health that 
is to be measured within an HRQoL measure.	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clinical and experimental psychologists to assess the extent to which questionnaires designed 
to measure abstract concepts such as intelligence or emotional functioning were truly 
measuring these constructs. Psychometrically designed HRQoL instruments measure the 
constructs underlying the many dimensions of HRQoL, such as vitality, pain, and role 
functioning, and provide a summary score relative to a minimum and maximum level of 
performance for each health concept (Lenert, 2000). 
Psychometrics is primarily focused on the construction and refinement of valid and reliable 
measurement instruments because the foundation for all rigorous research designs is the use 
of sound measurement instruments (DeVon, 2007). It is an iterative process used to develop 
and refine measures that are valid, reliable, responsive and effective in research and clinical 
work. Reliability, validity, and responsiveness are key indicators of the quality of an 
instrument and as such, these properties are important to the development of instruments that 
yield accurate and relevant data (Kimberlin & Winterstein, 2008). 
4.2.1 Validity 
Validity is the extent to which an instrument measures its intended constructs. Validity 
requires that an instrument be reliable, but an instrument may be reliable without being valid 
(Kimberlin & Winterstein, 2008). In other words, though it may yield the same score for the 
same patient over time, it may not be measuring the constructs that it was designed to 
measure. For example, an instrument purporting to measure anxiety may yield the same result 
for the same subject at different points in time, but rather than measuring anxiety, it may 
instead be measuring fatigue. 
Though it is common to reference the validity of an instrument, validity is actually not a 
property of an instrument itself. Rather, it is the extent to which interpretation of the results 
are warranted (Kimberlin & Winterstein, 2008). Tests of validity are intended to assess how 
well the instrument's results can be used to make inferences about a group of respondents. 
There are three main types of validity assessment: (1) content validity; (2) construct validity; 
and (3) criterion-related validity. A model of construct validity is shown in Figure 2. As 
mentioned previously, content validity is a more superficial type of validity that is judged 
qualitatively by considering how well the items in the instrument represent the constructs of 
interest. It can also be explored by assessing the number of missing responses per item, with 
the assumption that a question in which a high number of respondents have chosen not to 
answer may be upsetting or unclear in some way. Criterion-related validity involves assessing 
to what extent the scores of an instrument correlate with other measures of the same construct 
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that should be theoretically related. It can be argued that both content and criterion-related 
validity contribute to overall construct validity (Kimberlin & Winterstein, 2008). Content 
validity will be explored in this study as it relates to the quality of the translation. Criterion-
related validity will be used as a proxy for construct validity of the QLQ-LMC21 and will be 
used to assess the extent to which the results of the QLQ-LMC21 can be used to make 
inferences about the HRQoL of Norwegian patients with CRC liver metastases.  Support for 
criterion validity comes from evidence from each subtype of criterion validity: concurrent, 
convergent, and discriminant validity. 
 
4.2.1.1 Convergent and discriminant validity 
Convergent and discriminant validity are two subtypes of validity that make up construct 
validity.  They are used to assess how well the instrument is measuring similar and dissimilar 
concepts. In other words, they are related concepts that sit on opposite sides of a spectrum. 
Convergent validity is the correspondence, or convergence, between constructs or items that 
are theoretically similar. Consequently, discriminant validity is the capability of the 
instrument to differentiate, or discriminate, between constructs that are theoretically different 
(DeVon, 2007). It is assumed that scales measure distinctly different constructs, so it is ideal 
that items demonstrate discriminate validity by being less correlated with other scales than 
with its own. For example, it is assumed and hypothesized that item 39 of the abdominal pain 
scale of the QLQ-LMC21 will correlate to a much lesser degree to the activity/vigor, eating 
problems, or anxiety scales than to the abdominal pain scale. Said in another way, item 39 
should correlate to a higher degree with its own scale (the abdominal pain scale) than to other 
scales in the measure. 
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Multi-trait scaling is a way to explore whether the traits, what are being called dimensions and 
scales in this study, behave in the way they are expected to (Fayers, 2005). Multi-trait scaling 
techniques can be used to assess the convergent and discriminant validity between items and 
dimensions within a measure, called the multi-trait multi-item (MTMI) method, or between 
scales of several different instruments, called the multi-trait multi-method (MTMM). These 
methods are combined with a statistical test, such as Pearson’s correlation coefficient, to 
explore the relationships between the desired items/dimensions or methods/dimensions. 
4.2.1.2 Concurrent validity 
Another subtype of criterion-related validity is concurrent validity. In an assessment of 
concurrent validity, the scores of one instrument are correlated with the scores of another 
instrument of high quality, called the criterion measure. Scale convergent and discriminant 
validity is then assessed as a way to evaluate how the instrument compares to the criterion 
instrument. Both instruments are concurrently administered to the same subjects at the same 
time point in order for the scores to be able to be meaningfully compared. Ideally, the 
criterion measure is the "gold standard". "Gold standard" tests are considered to be the current 
standard in the field and exemplify quality and correctness of results (Claasen, 2005).  
Unfortunately, there is currently no gold standard for HRQoL instruments, but researchers 
often use a well-tested and well-known measure as a substitute for a "gold standard." Apolone 
et al., for example, used the SF-36 as the criterion in their comparison study of the SF-36 and 
QLQ-C30 in their evaluation of the construct validity, of the SF-36 (Apolone, 1998). 
4.2.2 Reliability 
Reliability refers to the extent to which the instrument will yield the same score each time it is 
administered and is free from measurement error. Reliability is necessary, but it is not 
sufficient for a measure to be considered useful (Fayers, 2005). According to classical test 
theory, any score obtained by a measuring instrument consists of both "true" score, which is 
unknown, and "error" of the measurement (Crocker L., 1986).  The true score is the score that 
the person would have received if the instrument were completely free of error, and the 
development and validation of measurement instruments, including HRQoL instruments, is in 
large part focused on reducing error in the measurement process (Kimberlin & Winterstein, 
2008). During development of an instrument, pilot testing is often used to identify error 
sources so that they can be reduced or eliminated.  
Reliability estimates are primarily used for three purposes: (1) to evaluate the stability of the 
instrument when given to the same patient at different time points (test-retest reliability); (2) 
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the equivalence of different observers scoring a behavior or event using the same instrument 
(inter-rater reliability); or (3) sets of items from the same test (internal consistency) 
(Kimberlin & Winterstein, 2008). Because of study design, this study will focus on internal 
consistency reliability estimates. However, in order to place reliability estimates within 
context and better describe why I have chosen to focus on internal consistency reliability, I 
will briefly describe test-retest and inter-rater reliability. 
The test-retest reliability of the instrument is determined by administering a test to the same 
individual at two different time points. The strength of the correlation between the two scores 
is then measured.  This type of reliability testing can be used for the testing of equipment, 
such as a scale. Ideally, the scores will be highly correlated to demonstrate a high degree of 
reliability and a low degree of measurement error. Test-retest reliability is not applicable in 
this analysis because this study is cross-sectional in design and patients were given the 
questionnaires at one particular point in time rather than at two or more points in time. 
With inter-rater reliability, the equivalence of ratings is established when an instrument is 
used by different observers. These instruments are used when a researcher wishes to observe 
and quantify the behavior of a subject or abstract data from medical charts or when diagnoses 
or assessments are made for research purposes. Equivalence of ratings is established to the 
degree that scores from different observers of the same phenomena correlate to each other. 
Inter-rater reliability is not applicable to this study because there are no third party observers 
involved in our measurement of patient HRQoL. 
4.2.2.1 Internal consistency reliability 
Internal consistency estimates establishes the reliability of sets of items from the same test 
(Kimberlin & Winterstein, 2008). These estimates are based on the assumption that items 
measuring the same construct should correlate to each other. For example, items that form a 
pain scale should correlate highly with one another because they were placed within the pain 
scale with the assumption that they measure the underlying construct of pain.  
Internal consistency reliability estimates can be evaluated both at the item level and at the 
scale level. At item level, it allows the reliability to be assessed at the micro-level. In a sense, 
the scale is dissected in order to view the parts that comprise the whole, and problematic items 
that may contribute to measurement error can be identified. This is especially helpful during 
measurement development or when assessing the equivalence of a newly translated measure, 
because problematic items that reduce instrument reliability can be identified and removed or 
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redeveloped. Apolone et al. focused on internal consistency reliability estimates in their 
comparison study of the Italian language QLQ-30 and SF-36 (Apolone, 1998). Loge et al. also 
chose this reliability estimate in their 1998 validation study of the Norwegian language SF-36 
(Loge, 1998). 
Internal consistency at scale level allows a macro-view of the scales and is usually assessed 
using a statistical coefficient called Cronbach’s alpha. At this level the scales can be assessed 
for overall reliability and compared with scales that are hypothesized to measure the same 
construct. This method is especially useful in the assessment of HRQoL instruments that take 
a modular approach, such as the EORTC line of instruments, because they are developed with 
the assumption that the sub-modules add valuable and complimentary HRQoL to the core 
module. The reliability of the corresponding scales in the core measure and the sub-module 
can be compared to assess the quality of the scales alone and together, and whether or not the 
sub-module adds any value to the core measure. Bergman et al. used internal consistency 
estimates to evaluate and compare the reliability of corresponding scales of the QLQ-C30 and 
lung cancer module QLQ-LC13 to assess if the QLQ-LC13 helped to increase reliability of 
the complimentary scales of the QLQ-C30 (Bergman, 1994).  
 4.2.3 Responsiveness 
The responsiveness of an instrument is defined as the ability of the instrument to measure 
small, but meaningful, underlying changes in HRQoL over time (Hays, 1993).  Essentially, it 
is the ability of a measure to identify a patient as changed or not changed by an intervention. 
Guyatt et al. operationalized the concept of responsiveness as separate from validity and 
reliability in their 1985 study (G. Guyatt, Walter, S., Norman, G., 1985). As many RCTs are 
designed to collect and analyze data over two or more points in time, Guyatt et al. argue that 
the usefulness of an instrument to measure change in persons over time is not only dependent 
on validity and reliability, but also on the ability and sensitivity to measure minimal clinically 
important differences (MCID). MCID can be defined as the smallest difference in score in the 
domain of interest that patients perceive as beneficial and which would necessitate a change 
in the patient's management (G. Guyatt, Jaeschke, R., Singer, J., 1989). An operationalization 
of MCID has evolved to help establish more rigorous standards of interpretation for HRQoL 
instruments, as the correct interpretation of HRQoL scores is integral to the correct 
assessment of intervention efficacy. However, there is no “gold standard” for MCID, and all 
estimates of MCID require a study-specific value judgment (Terwee, 2003). MCID is a very 
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important concept in the responsiveness of HRQoL measures used in RCTs, however, it is 
outside the scope of this analysis due to study design and will not be a topic of focus. 
There are several methods to investigate responsiveness, including evaluating effect size (ES), 
standardized response mean (SRM), the responsiveness statistic (RS), and floor and ceiling 
effects. ES, SRM, and RS are used to statistically calculate the responsiveness of an 
instrument when longitudinal data is available. Responsiveness by way of floor and ceiling 
effects can be explored visually and using response pattern distribution when cross-sectional 
data is available. Due to the cross-sectional design of this study, this analysis will focus on the 
floor and ceiling effects method. I will, however, briefly discuss the other methods that are 
used when longitudinal data is available. 
For the longitudinal methods, the numerator is the mean change and the denominators are the 
standard deviation at baseline (ES), the standard deviation of change for the sample (SRM), 
and the standard deviation of change in response to the intervention (RS). Each has their 
limitations, however. The ES statistic ignores variation in change entirely, the SRM ignores 
information about variation in scores for clinically stable respondents, and the RS ignores 
information in scores for clinically unstable respondents (Fayers, 2005). All three methods, 
however, may be used together to gather robust information about instrument responsiveness. 
Additionally, when the results of a clinical trial comparing an intervention of known efficacy 
with a control group are available, a useful measure of responsiveness is a between group t-
statistic for change scores (Fayers, 2005). The ability of an instrument to discriminate 
between two groups of patients adds powerful evidence for its usefulness. 
4.2.3.1 Floor and ceiling effects 
Responsiveness is how sensitive the instrument is to measuring particular health states. 
Because responsiveness is defined as how sensitive an instrument is to detecting underlying 
change, responsiveness hinges on the ability of an instrument to accurately capture any 
particular health state at any given point in time. Exploring floor and ceiling effects is a way 
to explore the responsiveness of a measure with a cross-section of patients, rather that using 
longitudinal data to compare HRQoL over several time-points. 
Floor and ceiling effects are studied to assess how well an instrument is able to measure the 
health states of patients in relatively good health and those in poor health, respectively. 
Ceiling effects are the insensitivity of an instrument to measure changes in low levels of 
disability. For example, a measure exhibiting ceiling effects would be insensitive to the 
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HRQoL gains of patients in relatively good health. Conversely, floor effects are the inability 
of an instrument to capture HRQoL movement when patients have moderate to severe health 
burdens. In other words, patients are worse off than the instrument can accurately capture 
(Feeny, 2013). If many patients score at either extreme of a scale, the instrument will have 
limited ability to register deterioration or improvement, respectively (Brazier, 1999). These 
underestimations of the magnitude of change can bias results of the intervention and 
economic evaluation.  
The potential for floor and ceiling effects can be assessed by analyzing response patterns. 
Loge et al., for example, used response patterns to analyze floor and ceiling effects in their 
exploration of the newly translated Norwegian language SF-36 study (Loge, 1998). Spikes at 
the highest and lowest response options are seen as evidence for ceiling and floor effects, 
respectively (Feeny, 2013). Intuitively, if a spike is seen at the high or low end of the 
distribution, one might infer that the instrument may have trouble differentiating between 
gradients in patients in either very good or very poor health.  
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5 Methods  
This study seeks to explore the methods used in (1) translating a HRQoL instrument and (2) 
assessing its psychometric quality in terms of validity, reliability, responsiveness, and 
equivalance. Because the translation process is inherently qualitative in nature and the 
subsequent psychometric assessment is quantitative, the methods have been divided 
accordingly:  (1) the translation process (qualitative); and (2) the psychometric assessment 
(quantitative).  
The psychometric assessment has been further divided into two sections: (1) content validity, 
psychometric validity, and equivalence of the QLQ-LMC21; and (2) scale reliability, validity 
and responsiveness in comparison to the SF-36 and QLQ-C30. Content validity, psychometric 
validity and equivalence are tested together because they use item-level tests to assess quality. 
It is important to first analyze an instrument from the item level because item-level quality is 
the foundation upon which scale level quality rests. Scale reliability, validity and 
responsiveness have been given their own section for two reasons: (1) they use scale-level 
tests to assess quality and (2) these tests involve comparison with other instruments (the 
QLQ-C30 and SF-36). 
5.3 Translation process methods 
This section will begin with the patients, data methods, and translators used during the 
translation of the QLQ-LMC21 and continue with the methods used, up to and including final 
acceptance of the translated questionnaire by the EORTC QoL Group. Content validity 
methods are discussed at the end of the section. 
5.3.1 Patients 
As part of the translation process, the intermediary version of the QLQ-LMC21 was pilot 
tested on adult Norwegian patients diagnosed with CRC liver metastases being treated at 
Rikshospitalet in Oslo. Inclusion criteria consisted of having a diagnosis of CRC liver 
metastases. 
5.3.2 Data 
Data during the translation process was collected in two manners: (1) from the translation 
process excluding pilot testing and (2) pilot testing on patients. Data from the former was 
considered feedback from translators, the EORTC QoL Group, and the outside translation 
agency contracted by EORTC to advise on translation quality. This data helped to inform the 
translation process and ultimately the intermediary questionnaire that was given to patients in 
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the pilot test. Consequently, feedback from patients involved in the pilot test was considered 
separately as its own data. 
5.3.3 Translators 
There were four translators involved in the Norwegian translation of the QLQ-LMC21. Two 
were needed to perform the forward translation from English to Norwegian, and an additional 
two were needed to perform the backward translation from Norwegian to English. The 
translators were selected based on their language skills, with all four translators having 
excellent spoken and written Norwegian and English skills. The two forward translators were 
current masters students in the Health Economics, Policy, and Management program at the 
University of Oslo. The first forward translator (FW1) lived in Norway as a small child and 
was educated in Norway through grade school. She then attended an American high school in 
the Dominican Republic, and afterwards returned to Norway to pursue higher education. She 
has resided in Norway for 16 years. The second forward translator (FW2) is a native 
Norwegian speaker who lived in Norway until she was 5 years old, then lived in the United 
States for 20 years and received formal education there through the college level. She has 
resided in Norway for the last 3 years. The two backward translators were previous masters 
students in the Health Economics, Policy, and Management program at the University of 
Oslo. Both the first backward translator (BW1) and the second backward translator (BW2) are 
native Norwegians who have lived and attended American schools both in Norway and 
abroad. 
5.3.4 Translation process  
The translation of the QLQ-LMC21 is the result of a collaborative effort between this author 
(acting as the translation coordinator) and the EORTC QoL Group. Translation was a multi-
step process that took place over the span of 7 months. Figure 3 illustrates the process. 
 
Figure 3. Translation process of the QLQ-LMC21 
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5.3.4.1 Preparation: April 28 2014 
Communication with the EORTC Quality of Life Group was established during the 
preparation phase. During this phase they provided this author with the version of the QLQ-
LMC21 that would be used in the translation process. Because EORTC maintains a large bank 
of questionnaire items that can be drawn upon in the creation of new EORTC instruments, 
some of the items in our initial version of the questionnaire had already been translated into 
Norwegian. The items that had been pre-translated on the initial QLQ-LMC21 are shared with 
other EORTC measures. The questionnaire instructions, 13 of 21 questionnaire items, and 
response categories were pre-translated into the Norwegian language, leaving only eight items 
to be translated during this process. During the preparation stage, two forward and two 
backward translators were recruited to perform the translations. 
5.3.4.2 Forward translation: May 9 to May 16 2014 
Both forward translators were sent an electronic version of the pre-translated questionnaire 
and given five days to independently complete the forward translations of the eight 
questionnaire items. They checked the instructions, pre-translated items, and response 
categories for errors as well. After the forward translations were completed, the translation 
coordinator and the two translators met via a video conference call to discuss and reconcile 
the two translations into a single cohesive questionnaire.    
 
During the call, the two versions of the translation were compared and discussed by the two 
translators, while this author coordinated the discussion and acted as mediator. The following 
criteria were used for a final conclusion:  
A. If both versions were identical, no changes were made. 
B. If there was a difference, the most appropriate translation was chosen: 
a. The sentence as close as possible to the original meaning, but also fitting into 
the Norwegian cultural setting.  
b. When a sentence in the two versions had the same meaning we chose the 
translation that patients would be more likely to understand and use.  
c. The shortest sentences.  
The following items were translated and discussed: 
33. Have you worried about losing weight? 
41. Have your skin or eyes been yellow (jaundiced)? 
44. Have you felt lacking in energy? 
46. Have you had trouble talking about your feelings to your family or friends?  
47. Have you felt stressed? 
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48. Have you felt less able to enjoy yourself? 
50. Were you worried about your family in the future? 
51. Has the disease or treatment affected your sex life (for the worse)? 
 
The two forward translations versions were reconciled into one document and ready for 
translation from Norwegian back to English. 
5.3.4.3 Backward translation: May 26 to June 11 2014  
To ensure that the eight translated items retained their original English meanings, the items 
were translated from Norwegian back to English (backward translation) by the two backward 
translators. Both translators were sent an electronic file containing only the eight Norwegian 
questionnaire items. To prevent the translators from searching for the original English version 
of the questionnaire and becoming biased in their translations, they were not informed about 
which questionnaire the items were from, only that they were from a HRQoL instrument for 
cancer patients. The translators were given 16 days to independently complete the backward 
translations. After the translations were completed, the translation coordinator and two 
translators met in-person to discuss and reconcile the two translations into one cohesive 
document. The original English version of the questionnaire was used during the meeting as a 
reference point, helping to guide the reconciliation process. 
The two backward translations were reconciled into one cohesive document, as well as any 
recommended changes to the forward translation due to conceptual weakness or grammatical 
or spelling errors. 
5.3.4.4 Feedback from EORTC: July 2014  
After the forward and backward translations were completed, a translation report detailing the 
translation process and preliminary first intermediary version of the QLQ-LMC21 was 
prepared and sent to EORTC so they could provide feedback, recommend changes, and send 
the questionnaire to an outside translation agency for review. 
5.3.4.5 Feedback from translation agency: August 2014 
EORTC sent the questionnaire to an outside translation agency to provide expert feedback, 
recommend changes, and ensure that the instrument was ready for pilot testing.  
5.3.4.6 Pilot testing: September 2014 to November 2014 
After feedback from the translation agency was received, the questionnaire was pilot tested on 
ten patients diagnosed with CRC liver metastases at Rikshospitalet to gather information 
about content validity, patient acceptance, and any potentially problematic items. 
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5.3.4.7 Final Acceptance of the QLQ-LMC21 by EORTC: November 2014 
Comments gathered from patients during the pilot testing were sent to the EORTC QoL 
Group for additional feedback and eventual final acceptance of the instrument.  
5.3.5 Content validity 
Content validity of the QLQ-LMC21 was explored during all levels of the translation process. 
Content validity was assessed during the forward and backward translations based on 
translator feedback, feedback from EORTC and the outside translation agency, and from 
patient feedback during pilot testing. During pilot testing, patients were interviewed by one of 
the principle investigators of the CoMet study (a Norwegian surgeon who is both fluent in 
Norwegian and very familiar with this patient population) and given a comment sheet after 
completing the questionnaire. They were asked to identify any items that they did not 
understand or felt were problematic in some way. They verbally communicated any feedback 
to the interviewer, as well as logged it on a comment sheet. Content validity was assessed 
qualitatively by way of patient feedback. 
5.4 Psychometric assessment methods 
This section begins with the patients and data used in the psychometric assessment of the 
QLQ-LMC21. The psychometric assessment has been divided into two sections: (1) content 
validity, psychometric validity, and equivalence of the QLQ-LMC21; and (2) scale reliability, 
validity and responsiveness in comparison to the SF-36 and QLQ-C30.  
5.4.1 Patients 
The QLQ-LMC21 was given to adult Norwegian patients participating in the CoMet study at 
Rikshospitalet in Oslo. Inclusion criteria consisted of a diagnosis of CRC liver metastases, 
and participation in the CoMet study. Patients included in this study were at various time-
points in the study. For example, some had not yet had the trial surgery, while others were at 
four weeks or four months past their surgery.  
5.4.2 Data 
Patients were given a 10-page packet consisting of the SF-36, QLQ-C30, and QLQ-LMC21 
questionnaires (in this order) during clinic visits and by post between December 2014 and 
April 2015. Patients self-administered the questionnaires at home and sent them back to 
Rikshospitalet by post. Pre-addressed and pre-postage paid envelopes were included to help 
facilitate a higher response rate. The questionnaires included patient identification numbers so 
that patient demographics could be collected and used in the analysis. Some patients 
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completed the questionnaire four weeks after randomization into the study, while others 
completed the questionnaire at four weeks or four months after surgery. 
5.4.2.1 Instrument scoring 
Scores for all instruments were calculated in Microsoft Excel based on the instructions of the 
instrument developers.	  
QLQ-C30 & QLQ-LMC21 
The scoring methods for the QLQ-C30 and QLQ-LMC are the same because they are both 
developed by EORTC. First, the raw score of each questionnaire was computed by averaging 
the items in each scale and also the single items: 
Raw Score = RS = (I1 + I2 +...+ In ) /n, where I1 + I2 +...+ In are the items in the scale 
Next, the raw scores were linearly transformed to obtain a score, S, from 0-100: 
Functional scales: S = [1-(RS-1)/range]*100 
Symptom scales, symptom single items, and global health status: S = [(RS-1)/range]*100 
 
Range was defined as the difference between the maximum possible value of RS and the 
minimum possible value. For example, the lowest value a patient could choose on a QLQ-
LMC21 item scale was one, while four was the highest, giving a range of three.  
As an example, the emotional functioning scale score of the QLQ-C30 was calculated in the 
following way: 
RS = (Q21 + Q22 + Q23 + Q24) / 4 
Scale score = [1 - (RS-1) / 3]*100 
All of the scales and single-item scores range from 0 to 100, but the interpretation of 
functional scales and symptom scales and single items are different. A high score for a 
functional scale represents a high level of functioning, a high score for the global health status 
scale represents a high QoL, but a high score for a symptom scale/item represents a high level 
of symptomatology. (EORTC, 2001)  
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SF-36 
The SF-36 is scored in two steps. First, the response for each item is recoded with a value 
from 0-100 depending on the wording of the question (positively or negatively worded) and 
the range of values on the Likert scale. Values for the recoding of items can be found in Table 
4. Second, an average value is calculated for each of the recoded items in each scale. Missing 
data was ignored and the scale score calculated without the missing item, however if more 
than 50% of the items of any	  one scale are missing, the scale score was not calculated.	  
 
5.4.3 Content validity, psychometric validity, and equivalence of the QLQ-
LMC21 
All statistical analysis was performed using SPSS version 21. Microsoft Excel was also used 
for assessment of content validity, graphs and exploration of the data. 
The content validity, psychometric validity and equivalence of the Norwegian language QLQ-
LMC21 were explored first. These tests were conducted together because they explore the 
QLQ-LMC21 at (1) item level and (2) alone and not in comparison with any other measure. 
Content validity was evaluated by assessing the number of missing items. Establishing 
psychometric validity involves tests of both reliability and validity at the item level. Item 
internal consistency (a test of reliability) and item convergent and discriminant validity (tests 
of validity) were conducted using Pearson's Product Movement of Correlation (PPMCC) and 
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a multi-trait multi-item (MTMI) method matrix. Equivalence was assessed by patient 
acceptance, and tests of convergent and discriminant validity. 
5.4.3.1 Content validity 
Content validity of the QLQ-LMC21 was explored by assessing the distribution of responses 
for all items. Each item of the QLQ-LMC21 was tallied in an Excel spreadsheet in one of five 
categories, with four of the categories corresponding to the item range (1 – 4) and one 
category corresponding to a missing value. For example, if a patient answered 1 (“Ikke i det 
hele tatt”) for question 39, that response was tallied in category 1 for item 39. If the patient 
did not answer question 39, a tally was placed in the “missing” category. Patterns of missing 
items were then assessed. 
5.4.3.2 Psychometric validity 
Item internal consistency, item convergent validity, and item discriminant validity were 
assessed using Pearson's Product Movement of Correlation in combination with the MTMI 
method. 
Pearson Product Movement of Correlation 
Pearson’s coefficient, also known as the Pearson Product Movement of Correlation 
Coefficient (PPMCC), is often used to establish the validity of a measure. It is used as a 
measure of the degree of linear dependence between two variables and is used to test the 
correlation between sets of data as a measure of how well related they are. The formula for 
PPMCC can be expressed as: 
𝜌!,!   =    𝑥!   −   𝑥 𝑦!   −   𝑦𝜎!𝜎!  
Where X and Y being sets of values from two different scales, 𝑥! and 𝑦! represents each 
individual value in each scale. By calculating the difference of each value from the mean of 
each scale and multiplying them together, we get a new set of products of which the sum 
represents the covariance for X and Y. Because the values of X and Y are in different units, 
the covariance will be in the product of units for the scales, making it difficult to reason about 
the significance of the covariance. By dividing the covariance with the product of standard 
deviations for X and Y, we get a normalized value between -1 and 1 called the Pearson's 
correlation coefficient.  
As an example, we have the measurements of heights (cm) and weights (kg) of ten people, 
and the means of these heights and weights. If we wanted to find the PPMCC of these 
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subjects, we would subtract the mean of heights from the height of each person, multiplying 
each of these differences with the differences of weight from the mean for each person, and 
multiply the differences together. The sum of all these products would be the covariance, a 
measurement in cm-kg, which is difficult to interpret because cm and kg are measured on 
different scales. Dividing the covariance with the product of standard deviations would give a 
unit-less, normalized value within a continuous range between -1 and 1. Where the extreme 
values -1 and 1 represents a strong negative or positive correlation, respectively. And a value 
of 0 represents seemingly no correlation. PPMCC assumes a linear relationship between 
variables. A correlation of 0 might also mean the scales are not linear. 
When using PPMCC to evaluate validity of scales within an HRQoL measure, items within a 
subscale should correlate highly with each other (above .40) to demonstrate item convergent 
validity. Item discriminant validity is supported if the correlation between the item in question 
and its own scale is significantly higher (defined as two standard errors) than the correlations 
between the item and other scales. Mean scores and standard deviations of items within scales 
should also be very similar in order to confirm scaling assumptions (J. E. Ware, Gandek, B., 
1998).  
Multi-trait multi-item (MTMI) method 
The MTMI method allows the correlations between items and scales to be examined in order 
to gather evidence for convergent and discriminant validity.  When an instrument is 
developed, items are chosen for a scale with the assumption that they are measuring the 
intended construct. Ideally, measures should demonstrate convergent validity (to show that 
the item is measuring the hypothesized concept) by having items that correlate highly to its 
own scale. They should also demonstrate discriminant validity (to show that the item is not 
measuring an unintended concept) by correlating less to other scales. Item/scale correlations 
are the fundamental elements of multi-trait scaling, and constitute the MTMI correlation 
matrix (Fayers, 2005).  
Table 5 shows an example of a MTMI correlation matrix. Three different scales, or traits, are 
defined by items 1-10. Each row of the matrix contains correlations between the scores for 
one item and all hypothesized scales. Each column contains correlations between the scores 
for one scale and all the items in the analysis. Correlations between an item and its own scale 
should be corrected for overlap, so that estimates of the item-scale relationship are not 
erroneously inflated. Scale scores corrected for overlap are calculated by removing the item in 
question and computing the total scale score from the remaining items in that scale (Hobart, 
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Williams, Moran, & Thompson, 2002).  A variable X is correlated with the scale score S, 
where S = sum (X + other scale items), because X is in both terms. To examine to correlation 
of X with the scale, S must first be recalculated without X (Fayers, 2005). 
Item convergence is supported if an item correlates substantially (above .40) with the scale it 
is hypothesized to represent.  In Table 5, evidence for item convergent validity is supported 
because all items are highly correlated (>.40) with their own scales after the scales have been 
corrected for overlap. Item discriminant validity is supported if the highest correlation in a 
row of the matrix is the correlation between the item and the trait it is hypothesized to 
measure, and this correlation is significantly larger (>2SE) than other correlations in the row. 
The SE is the standard deviation of the sampling distribution of the statistic and can be used to 
refer to an estimate of the standard deviation derived from a particular sample. The SE acts as 
a confidence interval for the matrix, and because statistical significance is usually considered 
to be present when a test statistic lies within two standard deviations of the mean, the same 
assumption is applied to the MTMI matrix. If the correlations between the items and their 
hypothesized scales are within two SE, it cannot be stated with confidence that the between-
scale correlation is weak enough to be considered discriminant in nature. The data in Table 5 
shows evidence for discriminant validity because the correlations between the items and their 
hypothesized scales are greater than two SE (2 x .03 = .06) above the correlations between the 
items and the other scales. For example, if the correlation between item 1 and scale 2 had 
been .74 or higher, discriminant validity would not be supported for that item.  
 
Item internal consistency reliability 
Item internal consistency is a test of reliability and is the degree to which the items within a 
scale correlate with the other items in a scale, the overall scale, and different scales in an 
instrument. For example, it can be used to assess how well item 39 of the QLQ-LMC21 
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abdominal pain scale correlates with items 40 and 42 (which are also in the abdominal pain 
scale), the overall abdominal pain scale score, and the activity/vigor scale, eating problems, 
and anxiety scales.  It is evaluated to assess to what degree the items form a valid scale that 
measures what it purports to. Ideally, item 39 would correlate highly with items 40 and 42 
(which would demonstrate item internal consistency), and correlate to a lesser degree to the 
other three scales (which would demonstrate discriminant validity).  
To avoid inflated correlations between items and their own scales, scales were corrected for 
overlap by removing the item in question and computing the total scale score from the 
remaining items in that scale. For example, the Activity/Vigor scale consists of three items: 
questions 37, 43 and 44. To correct for overlap, the Activity/Vigor score scale was calculated 
three times, each time removing one of the questions from the scale. The scale score was 
calculated once without question 37 (only with the raw scores from questions 43 and 44), then 
without question 43 (only with the raw scores from questions 37 and 44), and finally without 
44 (only with the raw scores from questions 37 and 43). The individual items from each scale 
were then tested against both the corrected and uncorrected scale scores. Item internal 
consistency was considered the high and low range of Pearson’s correlation scores for an item 
in its own scale. For example, the item internal consistency for items 39, 40, 42 (abdominal 
pain scale) was considered only for the range of scores within the abdominal pain scale.  
Item discriminant validity 
Item discriminant validity range was considered to be the high and low range of PPMCC 
scores for the items and the scales for which they were not considered a part of. For example, 
discriminant validity for items 39, 40, and 42 (the abdominal pain scale) were observed for 
the activity/vigor, eating problems, and anxiety scales. 
Item convergent validity test 
An item convergent validity test was performed to assess the number of times the correlations 
of items within its own scale corrected for overlap had a higher PPMCC than .40. The number 
of items in each scale that scored above .40 were summed and divided by the total number of 
items in the scale. For example, in a scale of three items, if two of the PPMCCs of the items 
were above .40, then the convergent validity percentage would be 66.7%. The test can be 
illustrated in the following equation: 
Item  convergent  validity   =    𝑟! > 0.4!!! Ν  
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Where 𝑟! represents each correlation, if 𝑟! > 0.4 a 1 is tallied, otherwise a 0 is tallied. The final 
tally equals the number of correlations above 0.4, and dividing this by the number of 
correlations, N, gives the item convergent validity.  
Item discriminant validity test 
An item discriminant validity test was performed to assess the number of times the 
correlations of items within its own scale was significantly higher than its correlations with 
other scales. The test was considered a success when the item in the matrix row was (1) the 
highest correlation in the row; and (2) greater than two SE above all correlations. For 
example, if the SE of the correlation matrix was .03, two SE above would be .06. The number 
of significantly higher correlations was divided by the total number of correlations the item 
had with the other scales. For example, if an item in a pain scale were to have a PPMCC of 
.50 with the pain scale (its own scale), .50 would need to be the highest correlation in the 
item's row, and a correlation lower than .44 with any other scale would be considered a 
success of the item discriminant validity test. The total number of successes was divided by 
the total number of correlations. The test can be illustrated in the following equation: 
Item  discriminant  validity = Δ𝑟 > 2𝑆𝐸Ν    
Where  Δ𝑟 is the single difference between two correlations (the item with its own scale 
subtracted from the correlation of the item with another scale), SE is the standard error of the 
matrix table, and N is the number of total correlations for all items within a scale to the other 
scales. If Δ𝑟 is higher than two SE, the test is counted as a success. This test is completed for 
all items in a scale, and then the sum of successes is divided by the number of correlations of 
items with the other scales.  
5.4.3.3 Equivalence 
Equivalence with the English language version was established through the results of the 
content validity exploration and item convergent and discriminant validity tests. Equivalence 
was considered satisfactory when the instrument had a high degree of patient acceptance, and 
had a high degree of both convergent and discriminant validity (items within a scale scored 
above a .40 when corrected for overlap, and when items between scales scored two SE below 
the within-item-scale correlation). 
5.4.4 Reliability, validity and responsiveness 
To further assess the quality of the instrument, reliability and validity at the scale level were 
explored. Scale reliability of the QLQ-LMC21 was assessed using two methods: (1) using 
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tests of internal consistency reliability and (2) using reliability estimates of the comparable 
scales of the SF-36 and QLQ-C30.  Scale validity was assessed using tests of concurrent 
validity by comparing comparable scales of the QLQ-LMC21 to the SF-36 and QLQ-C30. 
Responsiveness was assessed in terms of floor and ceiling effects. 
Explorations of reliability, validity, and responsiveness were conducted together because (1) 
they examine the QLQ-LMC21 at scale level, rather than item level, and (2) they involve 
comparison with the SF-36 and QLQ-C30. These tests, however, are conducted using three 
different methods. Reliability is assessed using Cronbach's alpha because Cronbach's can only 
be used to assess reliability at the scale level. Concurrent validity is assessed using PPMCC, 
because as the goal is to explore how well comparable scales relate to each other, a measure 
of correlation is needed. Floor and ceiling effects are explored using response distribution 
between comparable scales. 
Comparable scales for all comparisons were: (1) abdominal pain scale of the QLQ-LMC21, 
pain scale of the QLQ-C30, and bodily pain scale of the SF-36; (2) activity/vigor scale of the 
QLQ-LMC21, fatigue scale of the QLQ-C30, and vitality scale of the SF-36; (3) anxiety scale 
of the QLQ-LMC21, emotional role functioning scale of the QLQ-C30, and mental health 
scale of the SF-362. The items from these scales can be found in Table 16 in the appendix.  
5.4.4.1 Reliability 
Scale reliability estimates are assessed using Cronbach's alpha. Cronbach's alpha was used in 
assessments of both internal consistency reliability and reliability estimates of the comparable 
scales of the QLQ-LMC21, SF-36, and QLQ-C30.	  
Cronbach's alpha 
Cronbach's alpha is a function of the average inter-correlations of items and the number of 
items in the scale, and it will generally increase as the inter-correlations among test items 
increase. Unlike PPMCC, which can provide data at item level, Cronbach's alpha should only 
be used to yield data at scale level. Cronbach's alpha tends to increase as the number of items 
in a scale increase, so using Cronbach's for a single item would yield a very low and 
inaccurate reliability estimate (DeVon, 2007). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  The SF-36 also has an emotional role scale, but upon investigation, the questions from the SF-36 mental health scale appeared to be more 
comparable to the QLQ-C30 emotional role functioning scale, and as such, a decision was made to compare the scales that were more similar 
in content rather than identical in name. The emotional role scale of the SF-36 contains items that ask how the respondent feels about how 
much the disease has impacted their everyday activities, while the mental health scale asks questions regarded their general emotional state. 
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Cronbach's alpha is used to measure the extent to which the items in a scale correlate with 
themselves and each other, or in other words, the extent to which they measure the same or 
differing constructs (Loge, 1998). Cronbach's alpha coefficients range from 0 to 1, with 
higher coefficients indicating higher levels of reliability. Nunnally et al. have recommended 
that an alpha of .70 or higher is needed to establish the reliability of a scale for group 
comparisons, such as group comparisons made in RCTs and other clinical studies (Nunnally, 
1978). However, very high reliability (above .95) can indicate that the items within the scale 
are redundant. (Nunnally, 1978)  George and Mallery have also recommended a gradient 
interpretation for alpha coefficients:  > .9 – Excellent, > .8 – Good, > .7 – Acceptable, > .6 – 
Questionable, > .5 – Poor, and < .5 – Unacceptable. (George, 2003) 
Cronbach's is frequently used in tests of reliability and is a function of the number of items in 
a test, the average covariance between item pairs, and the variance of the total score. It is 
expressed in the following formula: 
 
In the formula, K represents the number of items in the scale, while Vi represents each item's 
individual variance in the scale, of which we divide with VT, the total variance of the scale. 
Cronbach's alpha is expected to be a value between 0 and 1, however in practice, the value 
can range from negative infinity to 1. Negative Cronbach alphas imply a negative average 
covariance among items. Negative alphas can occur in small sample sizes due to sampling 
error, which produces a negative average covariance.  
Internal consistency reliability 
Internal consistency at scale level was assessed. Between-scale and overall scale reliability of 
the QLQ-LMC21 was tested using overall scale scores and Cronbach's alpha. Because it is 
desirable that scales in a measure do not correlate highly with each other, an alpha below .70 
was desirable for the between-scale tests. An alpha above .70, however, was desirable for 
overall scale reliability, as that is the recommended minimum to establish scale reliability. 
Reliability estimates of comparable scales 
The internal consistency reliability of the pain, fatigue, and mental health scales of the QLQ-
C30, QLQ-LMC21, and SF-36 were compared to each other using Cronbach’s alpha. The 
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reliabilities of these scales were first calculated separately. Because the SF-36 is separate 
from the QLQ instruments, the SF-36 scales remained isolated. The items from comparable 
scales of the QLQ-C30 and QLQ-LMC21, however, were then combined to explore whether 
or not the reliability of the scale was worsened or improved with the combining of the items. 
For example, the reliability of the pain scales for the QLQ-C30 (containing two items) and 
QLQ-LMC21 (containing three items) were calculated separately. The items in the scales 
were then combined for a total of five items, and the Cronbach’s alpha calculated. If the alpha 
was improved by the additional items from the second scale, the scales from both measures 
can then be seen as playing an integral role in the reliability of the combined use of the QLQ-
LMC21 and QLQ-C30. The reliability scores of the SF-36 scales were used only as the "gold 
standard" measure for comparison of the other two measures.   
Due to reverse scoring of 6 of the 11 items from the 3 scales of the SF-36 (items 7 and 8 from 
the pain scales, 9a and 9e from the vitality scale, and 9d and 9h from the mental health scale), 
the raw scores of the positively worded questions (or questions which had reverse scoring) 
were transformed so that a high score indicated better health. This maintains the consistency 
of the overall scoring scheme of the functional scales of the SF-36, where a higher score 
indicates better functioning and better health. All items were answered on a 5-point Likert 
scale with the exception of item 7, which is answered on a 6 point Likert scale. For example, 
question 9a from the Vitality scale asks “…how much of the time in the last 4 weeks did you 
feel full of life?” The answers range from: 1 = All of the time; 2 = Most of the time; 3 = Some 
of the time; 4 = A little of the time; 5 = None of the time. To maintain the consistency with 
the negatively worded questions, these answers were transformed into: 1 = None of the time; 
2 = A little of the time; 3 = Some of the time; 4 = Most of the time, 5 = All of the time. 
As with internal consistency reliability, a Cronbach's alpha of .70 was considered the 
minimum to establish scale reliability. Scores were also interpreted based on the gradient 
suggestions by George and Mallery. 
5.4.4.2 Validity 
PPMCC for comparable scales of the QLQ-LMC21, SF-36, and QLQ-C30 were compared in 
a multi-trait multi-method (MTMM) matrix to investigate concurrent validity between the 
instruments.	  
Multi-trait multi-method (MTMM) matrix 
The MTMM method was developed by Campbell and Fiske in 1959 as a way to 
simultaneously measure the correlations between different constructs that have been measured 
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by multiple methods (Campbell, 1959). It is one of the most common methods used to explore 
the construct validity of an instrument. The MTMM can be used whenever there are two or 
more constructs being measured with two or more methodologies. The methodologies that can 
be compared using the MTMM can either be completely different methodologies, like a 
standard paper and pencil questionnaire and direct observation by a researcher, or separate 
questionnaires that measure similar constructs. PPMCC is frequently used in the MTMM 
method as a way to measure the correlation between concepts. 
A matrix of traits and methods is built and convergent and discriminant validity is assessed 
based on the pattern of correlations between the traits and methods. Different measures of the 
same construct should correlate highly with each other (convergent validity) and different 
constructs should show low correlation with each other (discriminant validity) within the 
matrix (DeVon, 2007).  Figure 4 demonstrates an example of a MMTM matrix. 
Figure 4 is arranged by method and concept. For example, methods 1 and 2 could be different 
HRQoL instruments, and method 3 could be direct observation scores by a researcher. The 
concepts are the HRQoL concepts that the researchers wish to compare between methods, 
such as physical functioning, cognitive functioning, and fatigue. The methods are split up into 
blocks: mono-method blocks, and hetero-method blocks. The mono-method blocks consist of 
the correlations that share the same method of measurement. Within the mono-method blocks 
lay the hetero-trait mono-method triangles. These triangles contain the correlations for 
concepts that share the same method of measurement. It is possible to achieve relatively high 
correlations for these items because measuring different concepts with the same instrument 
results in a correlated measure. The mono-method blocks also include the correlations 
between the same concept within the same measurement. These scores will always be one 
because an item will always be perfectly correlated with itself.  
Conversely, the hetero-method blocks consist of the correlations that do not share the same 
methods. It is in the hetero-method blocks where convergent and discriminant validity can be 
assessed. The validity diagonals show the convergent validity, in other words, how well the 
same concept from different measurement methods correlate with each other. In figure 4 for 
example, the convergent validity of concept C1 and C3 is .53. Because these two measures 
are of the same concept, they are expected to highly correlate. 
The hetero-trait hetero-method triangles are where the discriminant correlations are expected 
to be found because these correlations differ by both measurement method and concept. The 
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correlation, for example, between C1 and B2 is lower than the correlation between C1 and C3 
functioning and fatigue at .10. This is expected because C1 and B2 are measuring different 
concepts, such as physical functioning.  
Concurrent validity 
Though there is no “gold standard” in HRQoL measures, the Norwegian language SF-36 has 
been used in Norway since its translation by Loge et al. in 1998 (Loge, 1998). The SF-36 will 
be treated as a “gold standard” for our purposes to explore the reliability and concurrent 
validity of the QLQ-LMC21 and test how well the scales of the QLQ-LMC21 correlate with 
other well-established variables that measure the same aspects of health. Additionally, 
complimentary scales of the QLQ-C30 are also compared to the QLQ-LMC21 and SF-36.  
Concurrent validity is the most commonly used type of construct validation. It focuses on the 
extent of the correlation among several measure of the same concept (Apolone, 1998). 
Concurrent validity was tested at scale level by constructing a MTMM matrix and comparing 
the pain, vitality/fatigue, and mental health/anxiety scales of the QLQ-LMC21, QLQ-LMC30, 
and SF-36 and assessing the convergent and discriminant validity of the scales in the hetero-
method blocks of the matrix. The correlations in the validity diagonals are considered to be 
evidence of convergent validity between instruments, while the correlations in the hetero-trait 
hetero-method triangles were considered to be evidence of discriminant validity between 
instruments. PPMCC values of .40 were needed in the validity diagonals to establish 
convergent validity. Correlations lower than those found in the hetero-trait hetero-method 
triangles were assumed to establish discriminant validity. 
Source: (Trochim, 2006) 
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5.4.4.3 Responsiveness 
Responsiveness of the QLQ-LMC21 in terms of floor and ceiling effects was explored using 
Excel to plot response distributions.  
Floor and ceiling effects 
Floor and ceiling effects were first tested by looking at the mean, standard error, worst 
possible score percentage, and best possible score percentage for the pain, vigor/fatigue, and 
mental health/anxiety scales for the QLQ-LMC21, QLQ-C30, and SF-36. Scale scores were 
examined for each patient for the presence of the best and worst possible scores. Due to the 
scoring being different for functional and symptom scales (higher scores are indicative of 
better health in the functional scales, while higher scores in the symptom scales are indicative 
of worse health), best and worst scores were considered differently depending on the type of 
scale. For the functional scales, those scoring 100 on the functional scales were considered to 
have the best scores, while those scoring 0 were considered to have the worst scores. It was 
the opposite for the symptom scales, meaning that those scoring 100 were considered to have 
the worst scores, while those scoring 0 were considered to have the best scores.  
After the best and worst scores for each scale were tallied, frequency distribution tables and 
graphs were then constructed for each scale mentioned above. Because the symptom scales of 
the QLQ-LMC21 and QLQ-C30 are scored in the opposite manner of the functional scales of 
the SF-36 (a low score on a symptom scale is desirable and indicates good health and a low 
amount of symptoms, whereas a low score on the functional scale indicates poor health and 
low functioning), the scores needed to be transposed before a meaningful comparison could 
occur. The QLQ-LMC21 and QLQ-C30 scales scores were transposed and placed into one of 
ten “buckets”. For example, a score of 0-10 for the QLQ-LMC21 or QLQ-C30 was assumed 
as being equivalent and comparable to a score of 90-100 on the SF-36. The ten buckets 
created were in intervals of 10: 0-10, 10-20, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-
100. Those scoring from 0-10 are those in the worst health, while those scoring 90-100 are 
those in the best health. 
Once scores were transposed into their appropriate buckets, data was then plotted into Excel 
and graphs created to show any left or right skewness in the distribution of scale scores. 
Because there is no consensus on how to define floor and ceiling effects mathematically, it 
was determined a priori that floor and ceiling effects were present when scale scores were 
found between 0 and 10, and 90 and 100, respectively. 
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6 Results 
The results will be structured in a similar way to the methods section. Results will be divided 
into three sections: (1) the translation process; (2) content validity, psychometric validity, and 
equivalence of the QLQ-LMC21; and (3) scale reliability, validity and responsiveness in 
comparison to the SF-36 and QLQ-C30.  
6.1 Translation results 
6.1.1 Patient characteristics 
As part of the translation process, the intermediary version of the QLQ-LMC21 was pilot-
tested on ten patients (eight males, two females) diagnosed with CRC liver metastases and 
being treated at Rikshospitalet in Oslo. All were native Norwegian speakers, with the 
exception of one native Swedish speaker. All patients completed the questionnaire and were 
interviewed in the hospital. They were between the ages of 57 and 77, with a mean age of 66 
years. Characteristics are shown in Table 6. 
 
	  
	  
6.1.2 Forward translation 
General comments regarding the translation 
The words "have you" have been translated as "har du" in other questionnaires. If possible 
(grammatically), the same translation was chosen. 
Items: 
Item 33: 
Original English version: Have you worried about losing weight? 
We felt that the FW2 version was more colloquial, straightforward, and written in a way that 
more people would understand. 
Forward translation: Har du bekymret deg for å gå ned i vekt? 
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Item 41: 
Original English version: Have your skin or eyes been yellow (jaundiced)? 
The word “gulaktige” translates to “yellowish” which we agreed would be a more appropriate 
word in Norwegian than “gule”, which translates to just “yellow.” 
Forward translation: Har huden eller øynene dine vært gulaktige (gulsott)? 
Item 44: 
Original English version: Have you felt lacking in energy? 
We decided that the word “mangler” was more appropriate because it translates into 
“lacking”, which is much less open to interpretation than the word “lite”, which could be 
more widely interpreted by patients than “mangler.” 
Forward translation: Har du følt at du mangler energi? 
Item 46: 
Original English version: Have you had trouble talking about your feelings to your family or 
friends? 
For consistency, the translation beginning with “har du” was chosen. 
Forward translation: Har du hatt vanskeligheter med å snakke om dine følelser med familie 
eller venner? 
Item 47:  
Original English version: Have you felt stressed? 
Both FW1 and FW2 had the same translation. 
Forward translation: Har du følt deg stresset? 
Item 48: 
Original English version: Have you felt less able to enjoy yourself? 
We felt the verb “å more” was a more suitable word in this context, as it is used in the 
reflexive to mean “to enjoy yourself.” “Å nyte” is usually not used in the reflexive and used to 
mean general enjoyment. We decided “å more” would be more easily understood by patients 
in the context of the survey question. 
Forward translation: Har du følt at du er mindre i stand til å more deg? 
Item 50: 
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Original English version: Were you worried about your family in the future? 
There was some question about the intended meaning of this question. After some discussion, 
we felt that this question was asking if the patient was worried about their family’s future. 
Therefore, we chose the FW2 translation. FW2 literally translated into “Have you worried 
about your family’s future”, while FW1 translated into “Were you worried about your family 
in the future”. FW1 is a direct translation of the English version, however we felt that FW2 
was written in a clearer way that more patients would understand. We also chose to begin the 
question with “har du” to maintain consistency with the other items. 
Forward translation: Har du vært bekymret for din families fremtid? 
Item 51: 
Original English version: Has the disease or treatment affected your sex life (for the worse)? 
There was some discussion regarding the parenthetical phrase at the end of the translation. 
FW2 translated this to (til det verre), while FW1 incorporated the parenthetical phrase into the 
question (på en negativ måte). We decided that FW1 retained the original meaning of the 
English version, while sounding better in Norwegian. 
Forward translation: Har sykdommen eller behandlingen påvirket sexlivet ditt på en negativ 
måte? 
6.1.3 Backward translation 
In one case, after discussion between the backward translators, changes to the original 
forward translation were made because it was decided that a more appropriate word could be 
used to better capture the original meaning of the question. 
Items: 
Item 33: 
Forward translation: Har du bekymret deg for å gå ned i vekt? 
Both backward translators translated this item back to the original English meaning, however, 
after some discussion, we decided that the word “vekttap” is the more appropriate word for 
unintentional weight-loss, rather than “å gå ned i vekt”, which could be interpreted to mean 
someone on a diet who is unable to intentionally lose weight. We decided that the original 
intention of the question was to ascertain the level of worry about unintentional weight-loss, 
as that is a common affliction with cancer patients. The first intermediary Norwegian version 
was changed from “Har du bekymret deg for å gå ned i vekt?” to “Har du bekymret deg for 
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vektap?” 
Change to forward translation: Har du bekymret deg for vekttap? 
Item 41: 
Forward translation: Har huden eller øynene dine vært gulaktige (gulsott)? 
BW1 chose “yellow-tinted” and BW2 chose “yellow” as a translation of "gulaktige". After a 
short discussion, we decided that “yellow-tinted” was a more direct translation of the 
Norwegian word “gulaktige” used in the Norwegian version of the item. It also makes more 
sense in Norwegian to describe skin as “yellow-tinted” rather than “yellow”. There was 
agreement that the backward translations were in agreement with the forward translations. No 
changes were made to the forward translation. 
Item 44: 
Forward translation: Har du følt at du mangler energi? 
BW1 used the phrase “felt at a loss of energy”, while BW2 used the phrase “experienced a 
lack of energy” as a translation of the forward translation. Through discussion, we decided 
that “felt at a loss of energy” better captured the original English item and better captures the 
perception of loss of energy. There was agreement that the backward translations were in 
agreement with the forward translations. No changes were made to the forward translation. 
Item 46: 
Forward translation: Har du hatt vanskeligheter med å snakke om dine følelser med familie 
eller venner? 
Both backward translations were similar to the original English text. There was agreement 
that the backward translations were in agreement with the forward translations. No changes 
were made to the forward translation. 
Item 47: 
Forward translation: Har du følt deg stresset? 
Both backward translations were similar to the original English text. There was agreement 
that the backward translations were in agreement with the forward translations. No changes 
were made to the forward translation. 
Item 48: 
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Forward translation: Har du følt at du er mindre i stand til å more deg? 
Though both translations essentially captured the original English version, there were 
differing phrases used to express enjoyment. BW1 used the phrase “less able to have fun”, 
while BW2 used the phrase “less capable of enjoying yourself” as a translation for "mindre i 
stand til å more deg". “I stand”, which is used in the Norwegian item, can mean either 
“capable” or “able” in the Norwegian language. However, “å more” more directly translates 
into “to have fun”, so we decided that BW1 was slightly more true to the original English 
item. Also, we discussed the connotation of “ability” vs. “capability”, with ability implying 
being able or not able to complete a task for various reasons, while “capability” implies 
having the capacity to complete or not complete a task. There was agreement that the 
backward translations were in agreement with the forward translations. No changes were 
made to the forward translation. 
Item 50: 
Forward translation: Har du vært bekymret for din families fremtid? 
There was some discussion in the forward translation about the intended meaning of this 
question, and it was decided that it was “Have you been worried about your family’s future?” 
It was then translated into Norwegian according to this meaning. Both backward translations 
were identical to this text. There was agreement that the backward translations were in 
agreement with the forward translations. No changes were made to the forward translation. 
Item 51: 
Forward translation: Har sykdommen eller behandlingen påvirket sexlivet ditt på en negativ 
måte? 
There was some discussion in the forward translation about the parenthetical phrase at the end 
of this question. It was decided that the parenthetical phrase would be incorporated into the 
main sentence. It was then translated into Norwegian accordingly. Both backward translations 
were identical to this text. There was agreement that the backward translations were in 
agreement with the forward translations. No changes were made to the forward translation. 
6.1.4 Feedback from EORTC 
EORTC recommended 1 change to the backward translation (item 41), and 2 changes to the 
intermediary version of the questionnaire (items 50 and 51). 
Backward translation recommended changes:  
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Item 41: 
Original English Version: Have your skin and eyes been yellow (jaundiced)?  
Backward translation: Have your eyes or skin been yellow-tinted (jaundice)? 
Recommended change: 
EORTC recommends that “skin” and “eyes” be switched in the sentence to match the original 
English version. 
New backward translation item: Have your skin and eyes been yellow-tinted (jaundice)? 
Intermediary questionnaire recommended changes  
Item 50: 
Original English Version: Have you worried about your family in the future?  
Questionnaire item: Har du vært bekymret for din families fremtid? 
Recommended change: 
EORTC advises that it would be better to say "family in the future" rather than "family's 
future" as the question asks about how the illness may indirectly affect patient`s family in the 
future rather than the future of the family - as in if family will break up or not. 
New intermediary questionnaire item: Var du bekymret for din familie i fremtiden? 
Item 51: 
Original English Version: Has the disease or treatment affected your sex life (for the 
worse)? 
Questionnaire item: Har sykdommen eller behandlingen påvirket sexlivet ditt på en negativ 
måte? 
Recommended change: 
To remain consistent with the original English version, EORTC recommends putting “for the 
worse” in brackets, as in the English version. 
New intermediary questionnaire item: Har sykdommen eller behandlingen påvirket ditt 
sexliv (til det verre)? 
These changes were implemented and the intermediary questionnaire was sent to EORTC for 
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proofreading by an outside translation agency. 
6.1.5 Feedback from translation agency 
The outside translation agency recommended three changes to the intermediary questionnaire, 
items 46, 49, and 51. No explanation for the changes was given and can only be inferred. 
Item 46: 
Questionnaire item: Har du hatt vanskeligheter med å snakke om dine følelser med familie 
eller venner?  
Recommended change: Har du hatt vanskeligheter med å snakke om følelsene dine med 
familie eller venner? 
This change is assumed to have been recommended because the translation agency felt that 
"følelsene dine" has a better flow in Norwegian than "dine følelser". Both have the same 
meaning but may sound better to a Norwegian speaker. 
Item 49: 
Questionnaire item: Har du vært engstelig for helsen din i fremtiden?  
Recommended change: Har du vært bekymret for din fremtidige helsetilstand? 
Question 49 was not part of forward and backward translation process because it was one of 
the pre-translated items furnished by EORTC. The translation agency used in this process 
decided to completely change this question from its previous form. They disagreed with the 
use of the word "engstelig" as a translation for the original English word "worried", the use of 
the word "helse" for a direct translation of the original English word "health", and decided to 
change the noun "fremtiden" into the adjective "fremtidige" as a translation for the phrase 
"future health".  "Engstelig" means anxious, while "bekymret" is a direct translation of 
"worried". While both words can be interpreted as responses to some sort of threat, worry 
may be perceived as the thought process that leads to anxiety, so someone may be worried, 
but not necessarily anxious. Anxiety may also be perceived as a more severe state-of-mind 
than worry. Patients who answer this question when it contains the word "engstelig" may 
answer this question differently than they would if the item used the word "bekymret" 
because the words imply different emotional states. Though "helse" is a direct translation for 
the original English word "health", "helsetilstand" means health condition, which is implied 
by the use of the word "helse" in the original Norwegian item. The translation agency decided 
that it was better to be explicit rather than implied in the item. 
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Item 51: 
Questionnaire item: Har sykdommen eller behandlingen påvirket ditt sexliv (til det verre)?  
Recommended change: Har sykdommen eller behandlingen påvirket sexlivet ditt (negativt)? 
Similar to the change recommended for item 46, the translation agency felt that “sexlivet ditt” 
had a better flow in Norwegian than “ditt sexliv”. They also disagreed with the direct 
translation from the English item of the parenthetical phrase “til det verre”, and simplified 
with the word “negativt”.  
These recommended changes were implemented in the first intermediary version of the QLQ- 
LMC21. 
6.1.6 Pilot testing of the first intermediary version of QLQ-LMC21 
Most patients reported no difficulties in completing the questionnaire. None of the questions 
were upsetting to the patients or contained difficult words. One patient expressed concern 
with questions 38 and 50. The word “kribling” in question 38 was noted as referring more to a 
tingling sensation than to the loss of sensation and numbness that the patient experiences as a 
side-effect of chemotherapy for the disease. This patient also noted for question 50 that he 
preferred the phrasing “Har du vært bekymret for din familie i fremtiden” over “Var du 
bekymret for din familie i fremtiden” because the former is consistent with the phrasing of the 
previous questions in the questionnaire. Another patient reported a difficulty with question 51. 
She was not certain if her age, disease, or treatment was affecting her sex-life and was 
uncertain how to answer the question. 
6.1.7 Final acceptance of QLQ-LMC21 from EORTC 
The translation report was updated with the results from the pilot testing and sent to EORTC 
for final review. EORTC requested the item 50 remain consistent with the English version and 
the item version “Var du bekymret…” was selected to remain in the final version of the 
instrument. EORTC noted the word “golsot” in question 41 as misspelled. The spelling was 
changed from “golsot” to “gulsott” and the final Norwegian translated version of the QLQ-
LMC21 was accepted by the agency and made available in their database for widespread use 
by researchers.  
6.1.8 Content validity 
The multi-layered and iterative translation process identified and corrected a number of 
potential weaknesses of the instrument. For example, the backward translators were able to 
offer a better translation for item 33, which was ultimately accepted by EORTC and is now a 
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part of the final version of the questionnaire.  Also, having four translators in agreement on 
most of the questions was also helpful in reinforcing the assumed quality of the questionnaire 
items. During pilot testing, most patients reported no difficulties in completing the 
questionnaire. None of the questions were upsetting to the patients or contained difficult 
words.  
6.2 Content validity, psychometric validity and equivalence results 
6.2.1 Patient characteristics 
After pilot testing and final acceptance by the EORTC QoL Group, the QLQ-LMC21 was 
administered to 22 patients participating in the CoMet study. The mean age was 68, with 
patients ranging in age from 49-86. There were 12 men (54.5%) and 10 women (45.5) with an 
average time since primary CRC diagnosis of 10.4 months. Table 7 shows patient 
characteristics for the psychometric assessment. 
 
6.2.1 Content validity 
Content validity of the QLQ-LMC21 was explored using response distributions to see the 
non-response rate of each item. Response distributions are found in Table 17 in the appendix. 
Of the 21 items of the instrument, there were three items with missing responses. Items 35 
and 37 each had one missing response (4.5%), while question 51, which asks about sexual 
function, had three missing responses (13.6%). Out of these three items, only item 51 was a 
newly translated item translated in this study. It was, however, not surprising that question 51 
had a relatively high missing response rate because it asks about sexual habits. Patients may 
find questions about sex sensitive or offensive. In terms of patient acceptance, content validity 
is assumed to be good. 
6.2.2 Psychometric validity 
The psychometric validity of the QLQ-LMC21 was assessed in terms of item internal 
consistency, item convergent validity, and discriminant validity using PPMCC to correlate 
individual items to each scale. Table 8 displays the results in an MTMI matrix, while table 9 
displays the summated results of item internal consistency and the convergent and 
	  	  
	  
54	  
discriminant validity tests.  Generally, the internal consistency for the items of all four scales 
was good, with all but two items exceeding the standard of .40 with significance. Item 42 
from the abdominal pain scale had a PPMCC of -.01, and item 47 from the anxiety scale had a 
PPMCC of .38. However, neither of the scores was significant.  
The instrument performed well in terms of item discriminant validity. In all but four 
correlations (item 42 and item 44), the item in question scored significantly higher (>2SE, 
where the SE of the correlation matrix was .06, meaning two standard errors above was .12.) 
with its own scale than with other scales. These results may indicate that there may be some 
construct overlap between item 42 and the three other scales, and item 44 and the abdominal 
pain and eating problems scales. 
Table 9 shows the results for the item convergent and discriminant validity tests. The 
activity/vigor and eating problems scales scored 100% in tests of item convergent validity, 
meaning all items in the scale scored above a .40. In the abdominal pain scale, two of the 
three items scored above .40, giving a convergent validity success rate of 66.7%. In the 
anxiety scale, 3 out of 4 items scored above .40, giving a success rate of 75%.  
The discriminant validity tests were just slightly more successful than the convergent validity 
tests. However, as with the convergent validity tests, only two of the four scales scored 100% 
success. The eating problems and anxiety scales scored 100%, meaning all item-correlations 
in the scales were significantly higher (>2SE) than the correlations between the items and the 
other scales. Due to item 42, the abdominal pain scale had only 6 of 9 significantly higher 
correlations, giving it the lowest rate at 66.7%. The activity/vigor scale had 7 of 9 
significantly higher correlations, giving it a success rate of 77.8%. Item 44 was problematic 
and scored within 2 SE of its own item-scale correlation with the abdominal pain and eating 
problems scales.  
It is important to note that due to a small sample size, the SE will be higher, thus lessening the 
likelihood of supporting item discriminate validity (Fayers, 2005). 
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6.2.3 Equivalence 
The standard for equivalence of the Norwegian language QLQ-LMC21 with the English 
language version was considered to be satisfactory when there was a high degree of patient 
acceptance of the measure, a within item-scale PPMCC of .40 for items corrected for overlap, 
and between-scale scores lower than two SE below the within item-scale correlation was 
Scale Item Mean SD N
Abdominal 
Pain Activity/vigor
Eating 
Problems Anxiety
39 1,47 0,84 19 ,58** ,40 ,34 -,02
40 1,56 0,84 19 ,75** ,49* ,31 ,16
42 1,32 0,75 19 -,01 ,48* ,02 ,29
37 2,28 0,83 18 ,49* ,67** ,43 0,53*
43 2,16 0,83 19 ,64* ,75** ,50* ,50*
44a 2,32 0,75 19 ,51* ,55** ,46* ,04
31 1,21 0,55 19 ,30 ,48* ,75** -,07
32 1,42 0,69 19 ,26 ,55* ,75** -,16
47a 1,16 0,37 19 -,03 -,15 -,26 ,28
48a 1,74 0,87 19 ,42 ,50* -,19 ,55**
49 2,11 0,74 19 ,12 ,34 ,13 ,70**
50a 1,79 0,86 19 ,04 ,28 -,15 ,64**
Standard error of the correlation matrix = .06
a translated item
Underlined values corrected for overlap
QLQ-LMC21 Symptom Scales
Table 8. QLQ-LMC21 Item means with standard deviations and their Pearson correlations with scales
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
Abdominal Pain
Activity/Vigor
Eating Problems
Anxiety
Scale # items Item internal consistency a Item discriminant validity b Item convergent validity test c Item discriminant validity test d
Abdominal Pain 3 (-).01 - .75 (-).02 - .49 66,7 66,7
Activity/vigor e 3 .55 - .75 .04 -.64 100 77,8
Eating Problems 2 ,75 (-).07 - .48 100 100
Anxiety e 4 .28 - .70 (-).26 - .42 75 100
e constains newly translated items
Table 9. Psychometric properties of the QLQ-LMC21
a Range of correlations between items and hypothesized scale corrected for overlap
b Range of correlations between items and other scales
c Item convergent validity scaling success (%) i.e. number of item-scale correlations greater than ,40/total number of correlations (corrected for overlap)
d Item discriminant validity scaling success (%) i.e. number of correlations of items with own scales significantly higher (> 2SE) than correlations with other scales/total number of correlations
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achieved. The instrument had a high degree of patient acceptance, with two items missing one 
response each, and one item missing three responses. Table 9 displays these results of the item 
convergent and discriminant validity tests. Two scales had convergent validity scaling 
failures, the abdominal pain scale and the anxiety scale, with item 42 at a -.01 and item 47 at 
.28. Neither score, however, has statistical significance. Two scales also had divergent 
validity scaling failures, the abdominal pain scale and the activity/vigor scale. Item 42 again 
caused the scaling failures for the abdominal pain scale, and item 44 of the pain scale scored 
within two SE of the correlation for its own scale.  
6.3 Reliability, validity and responsiveness results 
6.3.1 Internal consistency reliability 
Reliability of the QLQ-LMC21 scales was assessed using Cronbach's alpha. Results can be 
found in Table 10. Both between-scale alphas and overall scale alphas were calculated. The 
recommended standard of .70 was used to evaluate the reliability of the scales, with between 
scale scores below .70 desirable, but overall scale scores above .70 desirable. None of the 
between-scale scores were above .70. There were three of the four scales that scored an 
overall alpha of above .70, with the abdominal pain scale scoring .57.  
 
6.3.2 Reliability estimates of comparable scales 
Table 11 shows the exploration of the reliability of the corresponding scales of the SF-36, 
QLQ-C30, and QLQ-LMC21. The scales and questions compared can be found in Table 16 in 
the appendix. The reliabilities of the pain scales, vitality/fatigue/vigor scales, and mental 
health/emotional role-functioning/anxiety scales were calculated separately and in the case of 
the QLQ-LMC21 and QLQ-30, combined to explore if the reliability of the scales was 
increased or decreased when combined. 
 
The means for the scales of the QLQ-C30 and QLQ-LMC21 scales were similar. The biggest 
difference in means was between the emotional role functioning scale of the QLQ-C30 and 
Abdominal Pain Activity/vigor Eating Problems Anxiety Cronbach's alphas
Abdominal Pain 1 ,62 ,30 ,20 ,57
Activity/vigor a ,62 1 ,55 ,39 ,84
Eating Problems ,30 ,55 1 -,12 ,85
Anxiety a ,20 ,39 -,12 1 ,74
a contains newly translated items
Table 10. Correlations between QLQ-LMC21 scales and internal consistency using Cronbach's alphas
Scales
Correlation between scales
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the anxiety scale of the QLQ-LMC21 at 1.3 and 1.6, respectively, for a difference of .3. The 
range for the QLQ instruments is three, meaning the patient only has three response choices 
and makes for more compact means. The bodily pain scale of the SF-36 has a range of five, 
while the vitality and mental health scales have a range of four. Additionally, higher means 
for the SF-36 scales indicate better health. Lower scores on the QLQ instruments indicate 
better health, meaning that scores closer to 1 indicate better health.  
 
All scales scored above a .70 alpha with the exception of the abdominal pain scale of the 
QLQ-LMC21, which scored a .57.  
 
 
6.3.2 Concurrent validity 
Concurrent validity was assessed using a MTMM matrix. Results can be found in Table 12. 
The same three corresponding scales of the SF-36, QLQ-C30, and QLQ-LMC21 that were 
examined in the reliability analysis were compared here: the pain scales, vitality/fatigue/vigor 
scales, and mental health/emotional role-functioning/anxiety scales. All instruments scored 
above .40 with statistical significance in the (convergent) validity diagonals. Discriminant 
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validity was also unanimous, with no correlations in the triangles being higher than in the 
validity diagonals. 
 
For the QLQ-LMC21 and the SF-36, all correlations in the validity diagonal were above .70 
and statistically significant, giving evidence for convergent validity.  Correlations in the 
triangles were lower than the correlations in the validity diagonals, giving evidence for 
discriminant validity between these instruments for these three scales. However, three of the 
six correlations in the triangles were not found to be statistically significant. 
 
For the QLQ-LMC21 and the QLQ-C30, the correlations in the validity diagonals were above 
.6 and significantly significant, giving evidence for convergent validity. All correlations in the 
triangles were lower than those in the validity diagonals, also providing evidence for 
discriminant validity. As with the scales for the QLQ-LMC21 and SF-36, three of the six 
correlations in the triangles were not found to be statistically significant. 
 
The QLQ-C30 and SF-36 scored both the highest correlation in any of the validity diagonals 
(.91) and the highest correlation in any of the triangles (.68). The emotional role functioning 
scale of the SF-36 and the mental health scale of the SF-36 had a statistically significant 
correlation of .91, while the pain scale of the QLQ-LMC21 and the mental health scale of the 
SF-36 had a statistically significant correlation of .68, Also, three of the six correlations in the 
triangles were not significantly significant. These results, however, provide evidence for both 
convergent and discriminant validity. 
6.3.3 Responsiveness 
Responsiveness in the form of floor and ceiling effects was explored by first analyzing the 
best and worst possible scores for the three comparable scales of the QLQ-LMC21, QLQ-
C30, and SF-36. Results are found in Table 13.  Floor effects (percent with minimum score) 
ranged from 0%-4.5%. The pain scale of the QLQ-C30 was the only measure where a patient 
received the lowest score possible. Ceiling effects (percent with maximum score) were much 
more varied and ranged from 9.1%-59.1%. The emotional role scale of the QLQ-30 had the 
highest percentage of best possible scores at 59.1%. The activity/vigor scale of the QLQ-
LMC21, fatigue scale of the QLQ-C30, and vitality scale of the SF-36 each had the lowest 
percentage at 9.1%.  
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Floor and ceiling effects for the comparable scales are also shown in Figures 5-7. Scores have 
been rescaled from 0-100, with 0 representing the worst health. There appear to be ceiling 
effects in the pain (Figure 5) and mental health (Figure 7) scales of the measures, with the 
vast majority of patients scoring in the top quartile of scores of all measures. The 
vitality/fatigue (Figure 6) scales appear to be a bit more normally distributed, with a majority 
of respondents scoring between 50 and 70. The anxiety/emotional role-functioning/mental 
health distributions (Figure 7) showed some tendencies for ceiling effects in the QLQ-C30 
and SF-36. The QLQ-C30 had 16 respondents and the SF-36 12 respondents achieve a score 
between 90 and 100, while the QLQ-LMC21 only had 3 respondents achieve the same. Half 
of patients (11) scored 80-90 points with the QLQ-LMC21, but on the whole patient scores 
were much more distributed than with the other mental health scales, with eight patients 
ranging in score from 10 - 80. The SF-36 only had two patients score below an 80, and the 
QLQ-C30 had three patients with a score below 80. 
Scales Mean (SE)
Worst 
possible 
score % (n)
Best 
possible 
score % (n)
QLQ-LMC21 Symptom Scales (0-100, 100 worst health)
Abdominal Pain 18.1 (4.5) 0 45.5 (10)
Activity/vigor 42.9 (5.7) 0 9.1 (2)
Anxiety 22.3 (4.1) 0 13.6 (3)
QLQ-C30 Symptom Scales (0-100, 100 worst health)
Pain 17.4 (6.0) 4.5 (1) 54.5 (12)
Fatigue 36.1 (4.7) 0 9.1 (2)
QLQ-C30 Functional Scale (0-100, 0 worst health)
Role Functioning - Emotional 89.8 (4.3) 0 59.1 (13)
SF-36 Functional Scales (0-100, 0 worst health)
Bodily Pain 73.8 (6.0) 0 40.9 (9)
Vitality 57.0 (4.6) 0 9.1 (2)
Mental Health 87.2 (3.3) 0 22.7 (5)
Table 13. Floor and ceiling effects - best and worst possible score percentages of comparable 
QLQ-LMC21, QLQ-C30, and SF-36 scales (N=22)
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7 Discussion 
7.1 Study objectives 
This study aimed to explore the methods used in the translation and psychometric assessment 
of HRQoL instruments and preliminarily assess the quality of the Norwegian QLQ-LMC21 in 
terms of reliability, validity, responsiveness, and equivalence with the English version. Both 
the translation and psychometric assessment were approached in a methodical, systematic and 
transparent way to increase the likelihood of developing a high quality instrument and 
subsequently accurately assessing its quality.  
7.2 Main findings 
7.2.1 Translation process 
The iterative nature of the forward and backward translation process was useful in finding 
weaknesses in the wording of questions that could potentially affect the content validity of the 
instrument and helped to improve the equivalence between the English and Norwegian 
versions. Content validity of the questionnaire as a result of the translation process, including 
pilot testing, is assumed to be good. 
The EORTC QoL Group was unwilling to accept any items on the Norwegian QLQ-LMC21 
that deviated in structure from the original English version, even if, arguably, the Norwegian 
item was made to be more clear and understandable to patients. For example, item 51 was 
modified by removing a parenthetical phrase and seamlessly incorporating it into the 
sentence. It was felt by all translators that when left with the parenthetical phrase, the sentence 
was redundant, and removing the parenthetical phrase was an effective way to improve the 
flow and clarity of the question without compromising conceptual, functional, linguistic 
equivalence with the English version of the questionnaire. EORTC, however, wishes to 
maintain absolute consistency with the English version to ensure equivalence. They may also 
be hesitant to accept structural changes to translated versions to avoid making changes to the 
original English versions. 
Another occurrence of note was the recommended change of item 49 by the outside 
translation agency during the translation process, as item 49 had previously been translated 
for another Norwegian language EORTC instrument and was provided to this study already 
translated. This highlights the subjective nature of the translation process and how it is very 
easy and possible to have translated instruments that do not maintain equivalence or 
consistency with the original version.  
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7.2.2 Psychometric assessment 
Item 51 (the sexual function item) was the only translated item to have problems with missing 
responses. As it is not unusual for patients to have difficulties with questionnaire items 
regarding sex, it is assumed that the translated measure has good patient acceptance and good 
content validity. In a study of cancer patient HRQoL by Fairclough and Cella in the US, the 
response rate for the item "I am satisfied with my sex life" was only 7% (Fairclough, 1996). 
The same study had a general non-response rate that ranges for each question from 0% to 
12%. Additionally, patients may be unsure whether to attribute any difficulties in their sex 
lives to the disease, treatment, other comorbid illnesses, or a consequence of being older in 
age and may simply choose to not answer the question. 
Generally, the psychometric quality of the QLQ-LMC21 was fair to good. Internal 
consistency was fair to good, with 10 out of 12 item correlations scoring above .40 within 
their own scales. Item discriminant validity tests fared just slightly better than item 
convergent validity tests, meaning that while the scales may not be measuring what they 
purport to be measuring, they may be more likely to be measuring discrete concepts. Item 42 
in the abdominal pain scale performed rather poorly and caused scaling failures in both the 
convergent and discriminant scaling tests. Item 42 asks if the patient has had back pain, which 
may be a peripherally associated symptom of liver metastases. However, it is possible that 
these patients attributed peripheral pain to their stomach region rather than their back and do 
not perceive the pain as back pain, causing this item to correlate poorly with the abdominal 
pain scale.  
Equivalence with the English version was acceptable. The instrument had high patient 
acceptance and fair to good results in the item convergent and discriminant validity tests, with 
item 42 causing a majority of the failures in this area. 
Scale reliability was fair, with one of the four scales (the abdominal pain scale) having a 
Cronbach's alpha below .70. The low reliability of the abdominal pain scale may be a 
consequence of item 42's poor performance. The two scales that contained newly translated 
items (activity/vigor and anxiety), however, scored .84 and .74, good and acceptable, 
respectively.  
The combined reliability estimates for the QLQ-LMC21 and QLQ-C30 were good, with all 
combined scores being over .70.  The abdominal pain scale of the QLQ-LMC21 was 
improved with the addition of the items from the QLQ-C30 pain scale score, helping to 
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overcome the negative effects of item 42. However, the combined reliability of the scales was 
less than the alpha (.83) of the QLQ-C30 pain scale alone, indicating that the QLQ-C30 may 
be more reliable alone than in conjunction with the QLQ-LMC21 abdominal pain scale. The 
reliabilities of the fatigue/vigor scales of the QLQ-C30 and QLQ-LMC21 were both improved 
to .88 when combined, indicating that these scales work better together. The emotional role 
functioning scale of the QLQ-C30 was very high at .93, while the anxiety scale of the QLQ-
LMC21 was .74. When combined with the anxiety scale of the QLQ-LMC21, the alpha 
dropped to a score of .90. Usually a drop in alpha with the addition of items is undesirable. 
Additionally, the reliabilities for the SF-36 were above .80 for all three scales, potentially 
pointing to the quality of the SF-36 and confirming the assumptions of this study that the SF-
36 can be used as a stand-in for a "gold standard" instrument. 
 
The concurrent validity of the three measures was good, with all measures showing a high 
degree of both convergent and divergent validity with each other. The QLQ-LMC21 
performed well against all measures in terms of convergent validity, providing evidence that 
the instrument is measuring the constructs it purports. However, the number of statistically 
insignificant correlations in the triangles makes it difficult to draw conclusions about the 
discriminant validity of the instrument. 
 
Ceiling effects appear to be present for two of the three scales compared, the pain and mental 
health scales, with the fatigue/vitality scores being more normally distributed. The most 
surprising finding was in the anxiety scale of the QLQ-LMC21. Only three patients scored the 
highest possible on this scale, as opposed to 16 for the QLQ-C30 emotional role-functioning 
scale and 12 for the SF-36 mental health scale. When thinking about scales that are assumed 
to measure similar constructs, one would assume that the distribution of responses would be 
similar between instruments, meaning that if ten people scored the highest score possible on 
one scale, the same ten people would in theory score the highest possible score on the 
comparable scale. That this did not happen for these particular scales could indicate that the 
QLQ-LMC21 is more able to discriminate between patients in the better health states for this 
scale, which would be congruent with the assumption that disease-specific measures are better 
at measuring small, yet significant changes in patient health. 
 
Despite the methodological approach taken with the psychometric assessment, the sample size 
and time horizon make it difficult to draw many conclusions about the quality of the 
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Norwegian translated QLQ-LMC21 because it is assumed that some of these results may be 
the result of a small sample size and would differ significantly with a larger sample size. If, 
however, these findings were to be duplicated in a larger study, I would be hesitant to 
recommend the use of the instrument due to the poor performance of the abdominal pain 
scale. Nonetheless, results of convergent and concurrent validity, reliability of all scales other 
than the abdominal pain scale, and responsiveness are positive and very promising.  
7.3 Limitations 
As with any research, there are limitations with this study and conclusions must be drawn 
carefully. The small sample size (22 patients) makes it difficult to make definitive conclusions 
because of the possibility that this data is non-normally distributed and not representative of 
this patient group as a whole. Additionally, small sample sizes can affect Cronbach's alpha 
calculations, leading to incorrect reliability data.  
Collecting HRQoL measurements from patients over several time points and statistically 
analyzing the results was outside the scope of this study due to the time horizon (4 months). 
Because of this, responsiveness was explored visually using floor and ceiling effects. It may, 
however, be difficult to draw definitive and statistically sound conclusions regarding an 
instrument's ability to measure change using this method. 
The ability to address the quality of the single symptom items (because psychometric 
assessment is only concerned with scaling assumptions and leaves single items ignored) was 
also outside the scope of this study due to the time horizon and study design. The performance 
of single symptom items is, however, important, and was largely unaddressed in this study 
with the exception of the content validity exploration.  
Additionally, the QLQ-LMC21 has not yet been studied extensively in its original English 
form, making comparisons and judgments about its quality even more difficult.   
7.4 Further studies/research 
Further research with a longitudinal study design and larger sample size could address the 
limitations present in this study, as well as several specific issues that were raised during the 
analysis. More research will allow more meaningful judgments to be made regarding the 
quality of the Norwegian version, the original English version, and other translated versions 
that may be developed in the future. 
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Additional tests of the abdominal pain scale with a larger sample size could help to clarify 
problems with item 42. Though item 42 performed very poorly in this analysis, it is not 
possible to make a definitive statement regarding its quality and appropriateness in the 
abdominal pain scale. A more robust study, however, may be able to explore these issues 
more fully, and possibly gather evidence for the removal of the item from the scale.  
The quality of single symptom items was outside the scope of this study, but it could be 
explored in a longitudinal study where both between-groups and within-groups differences 
could be measured. Their reliability could be assessed using the test-retest correlation, as was 
done by Wan et al. in their validation of the Chinese QLQ-C30 (Wan, 2008). Their quality 
could be further explored by using a between-groups (for example surgery groups) test to 
assess the ability of the items to accurately differentiate between groups and their ability to 
measure change over time (responsiveness), as was done by Tan et al. in their validation of 
the QLQ-C30 and breast cancer specific EORTC module in Singapore (Tan, 2014) and Wan 
et al. in 2008 (Wan, 2008), respectively. 
A longitudinal study using between groups and within group comparisons would also allow 
for more robust tests of responsiveness, such as effect size, standardized response mean, and 
the responsiveness statistic. The responsiveness of disease-specific instruments may be the 
biggest advantage they have over other instruments, therefore additional assessment of the 
responsiveness of the QLQ-LMC21 is important to determine whether or not it is better able 
to measure small changes in the HRQoL of CRC patients with liver metastases than other 
instruments, such as the QLQ-C30 or SF-36. 
The results of this study suggest that it may be possible to supplement the SF-36 with the 
QLQ-LMC21 for patients with CRC liver metastases, without using the core EORTC cancer 
measure, the QLQ-C30. The SF-36 serves an important function because it can be used to 
derive QALYs in an economic evaluation. The QLQ-LMC21 is also important because it may 
offer a greater degree of responsiveness to the health states of this patient group. The function 
of the QLQ-C30 is, however, less clear. Some may argue that it is unnecessary or even 
unethical to burden patients already suffering from pain, fatigue, and loss of function to fill 
out multiple questionnaires that may be redundant or even yield invalid or unreliable results. 
Furthermore, asking patients to fill out multiple questionnaires may lead to patients becoming 
fatigued or overloaded and providing inaccurate or incomplete data, leading to poor and 
counterproductive data quality. Further studies of the psychometric qualities of the QLQ-
LMC21 will cast more light on this subject. 	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8 Conclusion 
This study has offered a transparent glimpse into the rigorous process of translating and 
checking the quality of the QLQ-LMC21 for use in patients with CRC liver metastases in 
Norway. Additionally, outside of the initial validation study performed by Blazeby et al. in 
2009 (Blazeby et al., 2009), this is currently the only study that has explored and assessed the 
psychometric properties of the QLQ-LMC21. This study can serve as a starting point for 
further evaluation of the quality of the Norwegian QLQ-LMC21 and its ability to measure 
HRQoL in patients with CRC liver metastases, as well as to generally add to the limited 
worldwide body of knowledge for this instrument. With CRC rates rising for men and 
women, this instrument can serve an important role in evaluating interventions for this disease 
that improve HRQoL and extend patient lives. 
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Appendices 
Appendix I - Questionnaires 
	  
English version of the EORTC-QLQ-LM21
 
	  
	  	  
	  
II	  
	  
Pre-translated EORTC-QLQ-LMC21
 
	  
	  	  
	  
III	  
Norwegian EORTC-QLQ-LMC21
 
	  
	  
 
	  	  
	  
IV	  
Norwegian EORTC-QLQ-C30 
NORWEGIAN 
 
EORTC QLQ-C30 (versjon 3.0.) 
 
Vi er interessert i forhold vedrørende deg og din helse. Vær så vennlig å besvare hvert spørsmål ved å sette 
en ring rundt det tallet som best beskriver din tilstand. Det er ingen "riktige" eller "gale" svar. Alle 
opplysningene vil bli behandlet konfidensielt. 
 
Ditt navns forbokstaver:  
Født (dag, mnd, år): 

 
Dato (dag, mnd, år): 31 

 
  
 Ikke i det   Svært 
 hele tatt Litt En del mye 
1. Har du vanskeligheter med å utføre anstrengende  
 aktiviteter, slik som å bære en tung handlekurv  
 eller en koffert? 1 2 3 4 
 
2. Har du vanskeligheter med å gå en lang tur?  1 2 3 4 
 
3. Har du vanskeligheter med å gå en kort tur utendørs? 1 2 3 4 
 
4. Er du nødt til å ligge til sengs eller sitte i en stol  
 i løpet av dagen? 1 2 3 4 
 
5. Trenger du hjelp til å spise, kle på deg, vaske deg  
 eller gå på toalettet? 1 2 3 4 
 
 
I løpet av den siste uken: Ikke i det   Svært 
 hele tatt Litt En del mye 
 
6. Har du hatt redusert evne til å arbeide eller 
 utføre andre daglige aktiviteter?  1 2 3 4 
 
7. Har du hatt redusert evne til å utføre dine  
 hobbyer eller andre fritidsaktiviteter?  1 2 3 4 
 
8. Har du vært tung i pusten?  1 2 3 4 
 
9. Har du hatt smerter?  1 2 3 4 
 
10. Har du hatt behov for å hvile?  1 2 3 4 
 
11. Har du hatt søvnproblemer?  1 2 3 4 
 
12. Har du følt deg slapp?  1 2 3 4 
 
13. Har du hatt dårlig matlyst?  1 2 3 4 
 
14. Har du vært kvalm?  1 2 3 4 
 
Bla om til neste side 
	  	  
	  
V	  
	   	  
NORWEGIAN 
 
 
I løpet av den siste uken: Ikke i det   Svært 
 hele tatt Litt En del mye 
 
15. Har du kastet opp?  1 2 3 4 
 
16. Har du hatt treg mage?  1 2 3 4 
 
17. Har du hatt løs mage?  1 2 3 4 
 
18. Har du følt deg trett?  1 2 3 4 
 
19. Har smerter påvirket dine daglige aktiviteter?  1 2 3 4 
 
20. Har du hatt problemer med å konsentrere deg,  
 f.eks. med å lese en avis eller se på TV? 1 2 3 4 
 
21. Har du følt deg anspent?  1 2 3 4 
 
22. Har du vært engstelig?  1 2 3 4 
 
23. Har du følt deg irritabel?  1 2 3 4 
 
24. Har du følt deg deprimert?  1 2 3 4 
 
25. Har du hatt problemer med å huske ting?  1 2 3 4 
 
26. Har din fysiske tilstand eller medisinske behandling  
 påvirket ditt familieliv?  1 2 3 4 
 
27. Har din fysiske tilstand eller medisinske behandling 
 påvirket dine sosiale aktiviteter?  1 2 3 4 
 
28. Har din fysiske tilstand eller medisinske behandling  
 gitt deg økonomiske problemer?  1 2 3 4 
 
 
Som svar på de neste spørsmålene, sett en ring rundt det tallet fra 1 til 7  
som best beskriver din tilstand 
 
29. Hvordan har din helse vært i løpet av den siste uken? 
  
 1 2 3 4 5 6 7 
 
 Svært dårlig      Helt utmerket 
 
30. Hvordan har livskvaliteten din vært i løpet av den siste uken? 
 
 1 2 3 4 5 6 7 
 
 Svært dårlig      Helt utmerket 
 
 
© Copyright 1995 EORTC Study Group on Quality of Life. All rights reserved.     Version 3.0 
 
	  	  
	  
VI	  
Norwegian SF-36 
  
 
SF-36v2™  Health  Survey   1994, 2004 Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust.  
(IQOLA SF-36v2 Standard, Norway (Norwegian)) 
 
 
Din Helse og Trivsel 
 
 
Dette spørreskjemaet handler om hvordan du ser på din egen helse.  Disse 
opplysningene vil hjelpe oss til å få vite hvordan du har det og hvordan du er i 
stand til å utføre dine daglige gjøremål.  Takk for at du fyller ut dette 
spørreskjemaet! 
For hvert av de følgende spørsmålene vennligst sett et  i den ene luken som 
best beskriver ditt svar. 
 
1. Stort sett, vil du si at din helse er: 
Utmerket Meget god God Nokså god Dårlig     
   1    2    3    4    5 
 
 
 
2. Sammenlignet med for ett år siden, hvordan vil du si at din helse stort sett 
er nå? 
Mye bedre 
nå enn for ett 
år siden 
Litt bedre  
nå enn for ett 
år siden 
Omtrent den 
samme som 
for ett år 
siden 
Litt dårligere 
nå enn for ett 
år siden 
Mye dårligere 
nå enn for ett 
år siden 
    
   1    2    3    4    5 
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SF-36v2™  Health  Survey   1994, 2004 Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust.  
(IQOLA SF-36v2 Standard, Norway (Norwegian)) 
3 De neste spørsmålene handler om aktiviteter som du kanskje utfører i 
løpet av en vanlig dag.  Er din helse slik at den begrenser deg i utførelsen 
av disse aktivitetene nå?  Hvis ja, hvor mye?  
 
 
 Ja, 
begrenser 
meg mye 
Ja, 
begrenser 
meg litt 
Nei, 
begrenser 
meg ikke i 
det hele tatt 
    
 a Anstrengende aktiviteter som å løpe, løfte tunge 
gjenstander, delta i anstrengende idrett ....................................  1 .............  2 .............  3 
 b Moderate aktiviteter som å flytte et bord, 
støvsuge, gå en tur eller drive med hagearbeid ........................  1 .............  2 .............  3 
 c Løfte eller bære en handlekurv ................................................  1 .............  2 .............  3 
 d Gå opp trappen flere etasjer .....................................................  1 .............  2 .............  3 
 e Gå opp trappen én etasje ..........................................................  1 .............  2 .............  3 
 f Bøye deg eller sitte på huk .......................................................  1 .............  2 .............  3 
 g Gå mer enn to kilometer ..........................................................  1 .............  2 .............  3 
 h Gå noen hundre meter ..............................................................  1 .............  2 .............  3 
 i Gå hundre meter .......................................................................  1 .............  2 .............  3 
 j Vaske eller kle på deg ..............................................................  1 .............  2 .............  3
	  	  
	  
VIII	  
	   	  
 
SF-36v2™  Health  Survey   1994, 2004 Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust.  
(IQOLA SF-36v2 Standard, Norway (Norwegian)) 
4. I løpet av de siste 4 ukene, hvor ofte har du hatt noen av de følgende 
problemer i ditt arbeid eller i andre av dine daglige gjøremål på grunn av 
din fysiske helse? 
 Hele 
tiden 
Mye av 
tiden 
En del av 
tiden 
Litt av 
tiden 
Ikke i det 
hele tatt 
     
 a Du har måttet redusere tiden  
du har brukt på arbeid eller 
på andre gjøremål ............................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 b Du har utrettet mindre enn  
du hadde ønsket ...............................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 c Du har vært hindret i å utføre  
visse typer arbeid eller gjøremål ......  1 ..............  2 ..............  3 ..............  4 ..............  5 
 d Du har hatt problemer med å 
gjennomføre arbeidet eller  
andre gjøremål (f.eks. det  
krevde ekstra anstrengelser) .............  1 ..............  2 ..............  3 ..............  4 ..............  5 
 
 
5. I løpet av de siste 4 ukene, hvor ofte har du hatt noen av de følgende 
problemer i ditt arbeid eller i andre av dine daglige gjøremål på grunn av 
følelsesmessige problemer (som f.eks. å være deprimert eller engstelig)? 
 Hele 
tiden 
Mye av 
tiden 
En del av 
tiden 
Litt av 
tiden 
Ikke i det 
hele tatt 
     
 a Du har måttet redusere tiden  
du har brukt på arbeid eller 
på andre gjøremål ............................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 b Du har utrettet mindre enn  
du hadde ønsket ...............................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 c Du har utførte arbeidet eller  
andre gjøremål mindre grundig 
enn vanlig.........................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
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SF-36v2™  Health  Survey   1994, 2004 Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust.  
(IQOLA SF-36v2 Standard, Norway (Norwegian)) 
6. I løpet av de siste 4 ukene, i hvilken grad har din fysiske helse eller 
følelsesmessige problemer hatt innvirkning på din vanlige sosiale omgang 
med familie, venner, naboer eller foreninger? 
Ikke i det 
hele tatt 
Litt En del Mye Svært mye 
    
   1    2    3    4    5 
 
 
 
 
 
7. Hvor sterke kroppslige smerter har du hatt i løpet av de siste 4 ukene? 
Ingen Meget 
svake 
Svake Moderate Sterke Meget 
sterke      
   1    2    3    4    5    6 
 
 
 
 
 
8. I løpet av de siste 4 ukene, hvor mye har smerter påvirket ditt vanlige 
arbeid (gjelder både arbeid utenfor hjemmet og husarbeid)? 
Ikke i det 
hele tatt 
Litt En del Mye Svært mye 
    
   1    2    3    4    5 
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9. Disse spørsmålene handler om hvordan du har følt deg og hvordan du har 
hatt det de siste 4 ukene.  For hvert spørsmål, vennligst velg det 
svaralternativet som best beskriver hvordan du har hatt det.  Hvor ofte i 
løpet av de siste 4 ukene har du… 
 
 
10. I løpet av de siste 4 ukene, hvor ofte har din fysiske helse eller 
følelsesmessige problemer påvirket din sosiale omgang (som det å besøke 
venner, slektninger osv.)? 
Hele 
tiden 
Mye av 
tiden 
En del av 
tiden 
Litt av 
tiden 
Ikke i det 
hele tatt     
   1    2    3    4    5 
 
 
 Hele 
tiden 
Mye av 
tiden 
En del av 
tiden 
Litt av 
tiden 
Ikke i det 
hele tatt 
     
 a Følt deg full av liv? ..........................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 b Følt deg veldig nervøs? ....................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 c Vært så langt nede at ingenting 
har kunnet muntre deg opp?.............  1 ..............  2 ..............  3 ..............  4 ..............  5 
 d Følt deg rolig og harmonisk? ...........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 e Hatt mye overskudd? .......................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 f Følt deg nedfor og deprimert? .........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 g Følt deg sliten? .................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 h Følt deg glad?...................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 i Følt deg trett? ...................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
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11. Hvor RIKTIG eller GAL er hver av de følgende påstander for deg? 
 Helt 
riktig 
Delvis 
riktig 
Vet  
ikke 
Delvis 
gal 
Helt 
gal 
     
 a Det virker som om jeg blir 
syk litt lettere enn andre ...................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 b Jeg er like frisk som de  
fleste jeg kjenner ..............................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 c Jeg tror at helsen min vil 
forverres ...........................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 d Jeg har utmerket helse .....................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 
 
 
 
 
 
 
Takk for at du fylte ut dette spørreskjemaet! 
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Original English Text FW1 FW2 FW12
33. Have you worried about losing weight? Har du engstet deg for vekttap? Har du bekymret deg for å gå ned i vekt?
Har du bekymret deg for å gå ned i 
vekt?
41. Have your skin or eyes been yellow 
(jaundiced)?
Har huden eller øynene dine vært 
gulaktige (gulsot)? Har huden eller øynene dine vært gult (gulsot)?
Har huden eller øynene dine vært 
gulaktige (gulsot)?
44. Have you felt lacking in energy? Har du følt at du har lite energi? Har du følt at du mangler energi? Har du følt at du mangler energi?
46. Have you had trouble talking about your feelings 
to your family or friends?
Synes du det har vært vanskelig å 
snakke om dine følelser med familie og 
venner?
Har du hatt vanskeligheter med å snakke om 
dine følelser med familie eller venner?
Har du hatt vanskeligheter med å 
snakke om dine følelser med familie 
eller venner?
47. Have you felt stressed? Har du følt deg stresset? Har du følt deg stresset? Har du følt deg stresset? 
48. Have you felt less able to enjoy yourself?
Har du følt at du er mindre i stand til å 
more deg?
Har du følt deg mindre i stand til å nyte deg 
selv?
Har du følt at du er mindre i stand til å 
more deg?
50. Were you worried about your family in the 
future?
Bekymrer du deg for din familie i 
fremtiden? Har du vært bekymret om din families fremtid? 
Har du vært bekymret for din families 
fremtid? 
51. Has the disease or treatment affected your sex 
life (for the worse)?
Har sykdommen eller behandlingen 
påvirket sexlivet ditt på en negativ måte?
Har sykdommen eller behandlingen påvirket 
din sexliv (til det verre)? 
Har sykdommen eller behandlingen 
påvirket sexlivet ditt på en negativ 
måte?
Table 14. QLQ-LMC21 Forward translation process
First Intermediary Version Original English Text BW1 BW2
Har du bekymret deg for å gå 
ned i vekt?
33. Have you worried about 
losing weight?
Have you been worried about losing 
weight?
Have you been worried about losing 
weight?
Har huden eller øynene dine 
vært gulaktige (gulsot)?
41. Have your skin or eyes 
been yellow (jaundiced)?
Have your eyes or skin been yellow-
tinted (jaundice)?
Have your skin or your eyes been 
yellow (jaundiced)?
Har du følt at du mangler 
energi?
44. Have you felt lacking in 
energy? Have you felt at a loss of energy?
Have you experienced a lack of 
energy?
Har du hatt vanskeligheter 
med å snakke om dine 
følelser med familie eller 
venner?
46. Have you had trouble 
talking about your feelings to 
your family or friends?
Have you had difficulties speaking 
about your feelings with your family or 
friends?
Have you had difficulties talking about 
your feelings with family or friends?
Har du følt deg stresset? 47. Have you felt stressed? Have you felt stressed? Have you felt stressed?
Har du følt at du er mindre i 
stand til å more deg?
48. Have you felt less able to 
enjoy yourself?
Have you felt as if you are less able 
to have fun?
Have you felt that you are less 
capable of enjoying yourself?
Har du vært bekymret for din 
families fremtid? 
50. Were you worried about 
your family in the future?
Have you been worried about your 
family’s future?
Have you been worried about your 
family’s future?
Har sykdommen eller 
behandlingen påvirket 
sexlivet ditt på en negativ 
måte?
51. Has the disease or 
treatment affected your sex life 
(for the worse)?
Has your illness of treatment affected 
your sexlife negatively?
Has the disease or the treatment 
negatively affected your sex life?
Table 15. QLQ-LMC21 Backward translation process
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7 Hvor sterke kroppslige smerter har du hatt I løpet av de siste 4 ukene?
8
I løpet av de siste 4 ukene, hvor mye har smerter påvirket ditt vanlige arbeid (gjelder både arbeid utenfor hjemmet og 
husarbeid?
9 Har du hatt smerter?
19 Har smerter påvirket dine daglige aktiviteter?
39 Har du hatt smerter I mageregionen?
40 Har du følt ubehag I mageregionen?
42 Har du følt vondt I ryggen?
9a Har du følt deg full av liv?
9e Har du hatt mye overskudd?
9g Har du følt deg sliten?
9i Har du følt deg trett?
10 Har du hatt behov for å hvile?
12 Har du følt deg slapp?
18 Har du følt deg trett?
37 Har du vært mindre aktiv enn ønskelig?
43 Har du følt deg redusert?
44 Har du følt at du mangler energi?
9b Følt deg nervøs?
9c Vært så langt nede at ingenting kar kunnet muntre deg opp?
9d Følt deg rolig og harmonisk?
9f Følt deg nedenfor og deprimert?
9h Følt deg glad?
21 Har du følt deg anspent?
22 Har du vært engstelig?
23 Har du følt deg irritabel?
24 Har du følt deg deprimert?
47 Har du følt deg stresset?
48 Har du følt at du er mindre I stand til å more deg?
49 Har du vært bekymret for din fremtidige helsestand?
50  Var du bekymret for din familie I fremtiden?
QLQ-C30 Pain
QLQ-LMC21 Abdominal Pain
I løpet av den sisten uken:
I løpet av den siste uka:
SF-36 Vitality
Table 16. Comparable scales of the SF-36, QLQ-C30 and QLQ-LMC21
SF-36 Mental Health
QLQ-C30 Role - Emotional
QLQ-LMC 21Anxiety
Hvor ofte I løpet av de siste 4 ukene:
I løpet av den sisten uken:
I løpet av den siste uka:
Hvor ofte I løpet av de siste 4 ukene:
I løpet av den sisten uken:
I løpet av den siste uka:
QLQ-C30 Fatigue
QLQ-LMC21 Activity/vigor
SF-36 Bodily Pain
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SF-36 
Bodily 
Pain
SF-36 
Vitality
SF-36 
Mental 
Health
C30 
Pain
C30 
Fatigue
C30 Role 
Functioning 
- Emotional
LMC21 
Abdominal 
Pain
LMC21 
Activity/vigor
LMC21 
Anxiety
SF-36 Bodily Pain 1 .569** .677** -.862** -,327 .468* -.724** -.519* -.548**
SF-36 Vitality .569** 1 ,284 -.467* -.775** ,097 -.534* -.798** -,249
SF-36 Mental Health .677** ,284 1 -.682** -,165 .910** -,272 -,328 -.768**
C30 Pain -.862** -.467* -.682** 1 ,309 -.555** .658** .507* .556**
C30 Fatigue -,327 -.775** -,165 ,309 1 -,032 .522* .849** ,177
C30 Role 
Functioning - 
.468* ,097 .910** -.555** -,032 1 -,140 -,221 -.786**
LMC21 Abdominal 
Pain
-.724** -.534* -,272 .658** .522* -,140 1 .623** ,198
LMC21 Activity/vigor -.519* -.798** -,328 .507* .849** -,221 .623** 1 ,387
LMC21 Anxiety -.548** -,249 -.768** .556** ,177 -.786** ,198 ,387 1
*. Correlation is significant at the 0.05 level (2-tailed).
Table 20. Correlations between complementary scales of QLQ-LMC21, QLQ-C30 and SF-36
**. Correlation is significant at the 0.01 level (2-tailed).
Correlations
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Cronbach's 
Alpha
Cronbach's Alpha Based on 
Standardized Items
N of Items
,571 ,588 3
Mean Variance
Std. 
Deviation
N of Items
4,636 3,671 1,9160 3
Mean Minimum Maximum Range
Maximum / 
Minimum Variance N of Items
Item Means 1,545 1,409 1,636 ,227 1,161 ,014 3
Cronbach's 
Alpha
Cronbach's Alpha Based on 
Standardized Items
N of Items
,835 ,835 3
Mean Variance
Std. 
Deviation
N of Items
6,810 5,862 2,4211 3
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item Means 2,270 2,190 2,381 ,190 1,087 ,010 3
Cronbach's 
Alpha
Cronbach's Alpha Based on 
Standardized Items
N of Items
,735 ,723 4
Mean Variance
Std. 
Deviation
N of Items
6,682 5,370 2,3174 4
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item Means 1,670 1,182 2,136 ,955 1,808 ,164 4
QLQ-­‐LMC21	  Abdominal	  pain	  scale	  reliability	  statistics
Table	  21.	  QLQ-­‐LMC21	  comparable	  scale	  reliability	  statistics
Reliability Statistics
Scale Statistics
Summary Item Statistics
QLQ-­‐LMC21	  Anxiety	  scale	  reliability	  statistics
Reliability Statistics
Scale Statistics
Summary Item Statistics
Summary Item Statistics
Scale Statistics
Reliability Statistics
QLQ-­‐LMC21	  Vatigue/vigor	  scale	  reliability	  statistics
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Cronbach's Alpha
Cronbach's Alpha 
Based on 
Standardized Items
N of Items
,833 ,836 2
Mean Variance Std. Deviation N of Items
3,045 2,807 1,6755 2
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item Means 1,523 1,409 1,636 ,227 1,161 ,026 2
Cronbach's Alpha
Cronbach's Alpha 
Based on 
Standardized Items
N of Items
,836 ,838 3
Mean Variance Std. Deviation N of Items
6,048 3,248 1,8021 3
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item Means 2,016 1,952 2,095 ,143 1,073 ,005 3
Cronbach's Alpha
Cronbach's Alpha 
Based on 
Standardized Items
N of Items
,925 ,928 4
Mean Variance Std. Deviation N of Items
5,227 5,994 2,4482 4
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item Means 1,307 1,273 1,364 ,091 1,071 ,002 4
Table	  22.	  QLQ-­‐C30	  comparable	  scale	  reliability	  statistics
QLQ-­‐C30	  Fatigue	  scale	  reliability	  statistics
Reliability Statistics
Scale Statistics
Summary Item Statistics
QLQ-­‐C30	  Pain	  scale	  reliability	  statistics
Reliability Statistics
Scale Statistics
Summary Item Statistics
QLQ-­‐C30	  Emotional	  role	  functioning	  scale	  reliability	  statistics
Scale Statistics
Summary Item Statistics
Reliability Statistics
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Cronbach'
s Alpha
Cronbach's Alpha Based on 
Standardized Items
N of Items
,846 ,873 2
Mean Variance
Std. 
Deviation
N of Items
4,409 6,444 2,5384 2
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item 
Means 2,205 1,864 2,545 ,682 1,366 ,232 2
Cronbach'
s Alpha
Cronbach's Alpha Based on 
Standardized Items
N of Items
,810 ,828 4
Mean Variance
Std. 
Deviation
N of Items
12,955 12,141 3,4843 4
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item 
Means 3,239 2,818 3,545 ,727 1,258 ,120 4
Cronbach'
s Alpha
Cronbach's Alpha Based on 
Standardized Items
N of Items
,847 ,864 5
Mean Variance
Std. 
Deviation
N of Items
21,818 10,537 3,2460 5
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item 
Means 4,364 3,773 4,818 1,045 1,277 ,252 5
Reliability Statistics
Scale Statistics
Summary Item Statistics
SF-­‐36	  Mental	  health	  scale	  reliability	  statistics
Reliability Statistics
Scale Statistics
Reliability Statistics
Scale Statistics
Summary Item Statistics
SF-­‐36	  bodily	  pain	  scale	  reliability	  statistics
Table	  23.	  SF-­‐36	  comparable	  scale	  reliability	  statistics
SF-­‐36	  Vitality	  scale	  reliability	  statistics
Summary Item Statistics
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Cronbach'
s Alpha
Cronbach's Alpha Based on 
Standardized Items
N of Items
,793 ,796 5
Mean Variance
Std. 
Deviation
N of Items
7,682 10,703 3,2716 5
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item 
Means 1,536 1,409 1,636 ,227 1,161 ,014 5
Cronbach'
s Alpha
Cronbach's Alpha Based on 
Standardized Items
N of Items
,884 ,891 5
Mean Variance
Std. 
Deviation
N of Items
10,700 11,274 3,3576 5
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item 
Means 2,140 2,000 2,350 ,350 1,175 ,017 5
Cronbach'
s Alpha
Cronbach's Alpha Based on 
Standardized Items
N of Items
,904 ,912 8
Mean Variance
Std. 
Deviation
N of Items
11,909 20,277 4,5030 8
Mean Minimum Maximum Range
Maximum / 
Minimum
Variance N of Items
Item 
Means 1,489 1,182 2,136 ,955 1,808 ,109 8
Table	  24.	  QLQ-­‐C30	  and	  QLQ-­‐LMC21	  comparable	  scale	  reliability	  statistics
QLQ-­‐C30	  and	  QLQ-­‐LMC21	  vitality/fatigue	  combined	  scale	  statistics
Reliability Statistics
Scale Statistics
Summary Item Statistics
QLQ-­‐C30	  and	  QLQ-­‐LMC21	  pain	  scales	  combined	  statistics
Reliability Statistics
Scale Statistics
Summary Item Statistics
QLQ-­‐C30	  and	  QLQ-­‐LMC21	  emotional	  role	  functioning/anxiety	  combined	  scale	  statistics
Scale Statistics
Summary Item Statistics
Reliability Statistics
